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Liver fibrosis is a common consequence of various chronic liver diseases. Although transforming 
growth factor β 1 (TGFβ1) expression is known to be associated with liver fibrosis, the reduced 
clinical efficacy of TGFβ1 inhibition or the inefficiency to completely prevent liver fibrosis in 
mice with liver-specific knockout of TGF receptor II suggests that other factors can mediate liver 
fibrogenesis. As a TGFβ superfamily ligand, activin A signaling modulates liver injury by 
prohibiting hepatocyte proliferation, mediating hepatocyte apoptosis, promoting Kupffer cell 
activation, and inducing hepatic stellate cell (HSC) activation in vitro. However, the mechanism 
of action and in vivo functional significance of activin A in liver fibrosis models remain uncertain. 
Moreover, whether activin B, another ligand structurally related to activin A, is involved in liver 
fibrogenesis is not yet known. This study aimed to investigate the role of activin A and B in liver 
fibrosis initiation and progression. The levels of hepatic and circulating activin B and A were 
analyzed in patients with various chronic liver diseases, including end-stage liver diseases (ESLD), 
non-alcoholic steatohepatitis (NASH), and alcoholic liver disease (ALD). In addition, their levels 
were measured in mouse carbon tetrachloride (CCl4), bile duct ligation (BDL), and ALD liver 
injury models. Mouse primary hepatocytes, RAW264.7 cells, and LX-2 cells were used as in vitro 
models of hepatocytes, macrophages, and HSCs, respectively. The specificity and potency of anti-
activin B monoclonal antibody (mAb) and anti-activin A mAb were evaluated using Smad2/3 
luciferase assay. Activin A, activin B, or their combination were immunologically inactivated by 
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the neutralizing mAbs in mice with progressive or established liver fibrosis induced by CCl4 or 
with developing cholestatic liver fibrosis induced by BDL surgery. In patients with ESLD, NASH, 
and ALD, increases in hepatic and circulating activin B, but not activin A, were associated with 
liver fibrosis, irrespective of etiology. In mice with CCl4-, BDL-, or alcohol-induced liver injury, 
activin B was persistently elevated in the liver and circulation, whereas activin A showed only 
transient increases. Activin B was expressed and secreted mainly by the hepatocytes and other 
cells, including cholangiocytes, activated HSCs, and immune cells. Exogenous administration of 
activin B promoted hepatocyte injury, activated macrophages to release cytokines, and induced a 
pro-fibrotic expression profile and septa formation in HSCs. Co-treatment of activin A and B 
interdependently activated the chemokine (C-X-C motif) ligand 1 (CXCL1)/inducible nitric oxide 
synthase (iNOS) pathway in macrophages and additively upregulated connective tissue growth 
factor expression in HSCs. Activin B and A had redundant, unique, and interactive effects on the 
transcripts related to HSC activation. The neutralization of activin B attenuated the development 
of liver fibrosis and improved liver function in mice with CCl4- or BDL-induced liver fibrosis and 
largely reversed the already established liver fibrosis in the CCl4 mouse model. These effects were 
improved by the administration of additional anti-activin A antibody. Combination of both 
antibodies also inhibited hepatic and circulating inflammatory cytokine production in the BDL 
mouse model. In conclusion, activin B is a potential circulating biomarker and potent promotor of 
liver fibrosis. Its levels in the liver and circulation increase significantly in both acute and chronic 
states of liver injury. Activin B might additively or interdependently cooperate with activin A, 
which directly acts on multiple liver cell populations during liver injury and fibrosis, as the 
combination of both proteins increases pro-inflammatory and pro-fibrotic responses in vitro. In 
addition, the neutralization of both activin A and activin B in vivo enhances the preventive and 
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reversible effects of liver injury and fibrosis compared to that when activin B alone is neutralized. 
Our data reveal a novel target of liver fibrosis and the mechanism of activin B-mediated initiation 
of this process by damaging hepatocytes and activating macrophages and HSCs. Our findings 
show that activin B promotes hepatic fibrogenesis, and that targeting of activin B has anti-
inflammatory and anti-fibrotic effects, which ameliorate liver injury by preventing or regressing 
liver fibrosis. Antagonizing either activin B alone or in combination with activin A prevents and 
regresses liver fibrosis in multiple animal studies, paving way for future clinical studies.
14 
 
 INTRODUCTION 
1.1 Clinical aspects of liver fibrosis 
Liver diseases include a wide spectrum of progressive conditions such as hepatic steatosis, hepatic 
inflammation, viral hepatitis, alcoholic liver disease (ALD), nonalcoholic fatty liver disease 
(NAFLD), nonalcoholic steatohepatitis (NASH)1, hepatic fibrosis, liver cirrhosis, and 
hepatocellular carcinoma2. Liver disease is one of the leading causes of mortality in the US with 
3.9 million people (1.6% adult population) diagnosed with chronic liver disease in 20153. Liver 
fibrosis is the common consequence of various chronic liver diseases and results from the 
abnormal wound healing response with progressive and excessive production and deposition of 
extracellular matrix (ECM) or connective tissue along with chronic inflammation1. Infection of 
hepatitis C and B viruses is the most common cause of liver fibrosis. The other causes include 
alcohol consumption, obesity, insulin resistance or type II diabetes, hypertension, hyperlipidemia, 
autoimmune hepatitis, cholestasis, and chronic cholangiophaties4. The accumulation of ECM 
proteins distorts the hepatic architecture by forming a fibrous scar, and the subsequent 
development of nodules of regenerating hepatocytes characterizes advanced liver fibrosis or 
cirrhosis. The major clinical consequences of cirrhosis are hepatocyte dysfunction, portal 
hypertension, and hepatocellular carcinoma. Its severe or life-threatening complications include 
ascites, variceal hemorrhage, spontaneous bacterial peritonitis, coagulation disorders, and hepatic 
encephalopathy5. Therefore, the assessment of liver fibrosis and quantification of hepatic fibrotic 
tissue have become important for diagnosis, defining etiologies, guiding therapeutic strategies, and 
predicting prognosis. At present, the three major clinical approaches for measuring liver fibrosis 
are liver biopsy assessment, liver stiffness measurement, and circulating biomarker detection in 
the blood. Clinically, liver biopsy is considered the golden standard to assess the stage and grade 
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of liver fibrosis for diagnosis and therapeutic efficacy evaluation. The histological scoring systems 
include the five-stage meta-analysis of histological data in viral hepatitis (METAVIR), seven-stage 
Ishak, and three-stage Knodell fibrosis scoring systems6. The most commonly used METAVIR 
fibrosis scoring system includes F0 to F4 stages of liver fibrosis: F0, normal liver or no fibrosis; 
F1, portal fibrosis without septa formation; F2, portal fibrosis with few bridging or septa; F3, portal 
fibrosis with numerous portal to portal or portal to central bridging; F4, portal fibrosis with 
numerous portal to portal or portal to central bridging and nodule formation or cirrhosis. Portal to 
central fibrous bridging is associated with chronic biliary disease-related fibrosis, and portal to 
portal fibrous septa formation in liver fibrosis is caused by chronic viral hepatitis7. The histological 
patterns of liver fibrosis depend on their etiologies. In chronic viral hepatitis, liver fibrosis starts 
with portal enlargement as mild fibrosis; peri-portal fibrosis and portal to portal fibrous bridging 
as advanced fibrosis; and regenerative nodule formation as cirrhosis. In chronic ALD and NASH, 
liver fibrosis is characterized by peri-venular and peri-sinusoidal fibrosis distributed in the 
centrilobular areas. The histological changes are hepatocyte feathery degeneration, cholangiocytes, 
or bile ductular hyperplasia in cholestasis liver fibrosis8. However, the invasive histological 
assessment method is limited by patient unwillingness, pain, expense, associated complications, 
and sampling error. The blood tests for liver fibrosis include N-terminal propeptide of type III 
collagen (PIIINP), hyaluronic acid, and other circulating biomarkers, which might be contributed 
by extrahepatic diseases9. Measurement of liver stiffness by using elastography is a potential 
noninvasive alternative to assess liver fibrosis, although the application of this method is limited 
by its reliability and portability5 10. Clinically, there is an urgent need to identify an invasive 
circulating biomarker associated with severity of liver fibrosis which could assist diagnosis and 
guide therapeutic strategies. 
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In clinical patients and experimental models, liver fibrosis is reversible if the underlying liver 
injury causes are eliminated11. Its reversibility allows the possibility to develop therapeutic 
strategies to treat this disease. To understand the mechanism of regression of liver fibrosis, ECM 
producing myofibroblasts and activated macrophages are two main cell populations which have 
been focused to investigate. Myofibroblasts apoptosis, reduced fibrotic cytokines, upregulated 
increased collagenase activity and elimination of fibrous scars are major characters of regressed 
liver fibrosis12. Presently, although multiple factors have been recognized as pro-fibrotic regulator, 
clinical trials have not shown notable anti-fibrotic effect or causes severe adverse conditions 13 14. 
Liver fibrosis is a complicated process contributed by multiple cell populations, cross-talk of 
various signaling pathways and modified by epigenetic regulation.  At present, no effective 
medicines or Food and Drug Administration-approved molecules are available to treat liver 
fibrosis. Thus far, the only remedial treatment for late-stage cirrhosis is liver transplantation. 
However, this treatment is highly restricted because of the lack of donor organs and the 
incompatible clinical conditions of patients. Thus, developing an effective approach for preventing 
and regressing liver fibrosis has become an urgent and unmet clinical need.  
1.2 Cellular mechanism of liver fibrosis 
The liver is constituted by parenchymal cells (hepatocytes and cholangiocytes) and non-
parenchymal cells, including hepatic stellate cells (HSCs), macrophages, neutrophils, T cells, 
natural killer cells, liver sinusoidal endothelial cells, and progenitor cells15. The cellular and 
molecular mechanisms underlying the initiation and progression of liver fibrosis are not 
completely understood. Multiple cell populations, including hepatocytes, macrophages, and, 
particularly, HSCs, cooperatively modulate the formation and resolution of liver fibrosis. The 
crosstalk between various liver cell types and between different molecular signaling pathways has 
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drawn more attention recently in order to identify the key mediators and thus the potential 
therapeutic targets of this pathogenesis16. Irrespective of the etiologies, including hepatitis virus 
infection and alcohol consumption, hepatocytes, cholangiocytes, and endothelial cells are 
damaged and release damage-associated molecular patterns (DAMPs) and reactive oxygen species 
(ROS), which directly activate HSCs, Kupffer cells, and other immune cells17 18. Accumulating 
evidence shows that myofibroblasts, as liver fibrogenic cells, drive the fibrogenic response and 
play a key role in hepatic fibrogenesis19. Hepatic myofibroblasts are mainly derived from activated 
HSCs and portal fibroblasts, whereas a small population originates from extrahepatic precursors. 
Activated Kupffer cells and other immune cells secrete cytokines and growth factors, including 
transforming growth factor beat (TGFβ), tumor necrosis factor (TNFα), interleukin 1 beta (IL-1β), 
interleukin-6 (IL-6), and chemokine (C-C motif) ligand 2 (CCL2), which along with ROS and 
DAMPs activate HSCs and trans-differentiate them to myofibroblasts to produce fibrillar collagen, 
fibronectin, and laminin20. These cytokines and growth factors also suppress matrix 
metalloproteinase (MMP) expression and promote tissue inhibitor of metalloproteinase (TIMP-1) 
transcripts to inhibit ECM degradation21. Excessive ECM accumulation and fibrous scar formation 
are the characteristic features of liver fibrosis. Fibrous scar tissue formation, hepatocyte loss, 
chronic inflammation, and liver architecture destruction eventually lead to liver dysfunction or 
failure15. While myofibroblasts are the central effectors of fibrogenesis, injured hepatocytes, 
endothelial cells, or bile duct epithelial cells, as well as activated macrophages and other immune 
cells, participate in the initiation and progression of liver fibrosis (Figure 1.1). Herein, we focus 
on reviewing the roles of hepatocytes, macrophages, and myofibroblasts in liver fibrosis 
development. 
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Figure 1.1 The cellular mechanism of liver fibrosis.  
Nishikawa K, Osawa Y, Kimura K. Int. J. Mol. Sci. 2018 
 
Hepatocytes 
Hepatocytes, as liver parenchymal cells, are the major cell type in the liver and constitute 
approximately 60% of liver cells and up to 80% of liver mass. Another 40% of liver cells are non-
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parenchymal cells, including Kupffer cells, HSCs, natural killer cells, lymphocytes, and liver 
sinusoidal endothelial cells22,23. The fundamental function of hepatocytes is to mediate lipid, 
carbohydrate, and protein metabolism to maintain homeostasis. Hepatocytes also produce albumin, 
clotting factors, lipoproteins, and bile acids. In addition, they detoxify toxic compounds, modify 
chemicals, and mediate urea metabolism and gluconeogenesis23.  
 
Hepatocytes participate in all the three phases of the liver injury process: initiation, perpetuation, 
and resolution24. The initial response to liver injury is hepatocyte stress and death, which leads to 
the release of ROS and DAMPs. Hepatocyte death is reflected by elevated serum alanine 
transaminase (ALT) and aspartate transaminase (AST), which are clinically used liver injury 
markers. ROS are the major stimuli to activate HSCs and macrophages. They also stimulate 
hepatocytes to increase TGFβ expression. As a representative ROS, hydrogen peroxide induces 
the activation of mitogen-activated protein kinase (MAPK) signaling pathway to activate multiple 
nuclear factors, including nuclear factor κB and nuclear factor erythroid-derived factor 2, in 
hepatocytes25 26. In chronic liver diseases, DAMPs from dying hepatocytes prompt inflammation 
and are represented by high-mobility group protein 1 (HMGB1) that in turn recruit inflammatory 
cells. DAMPs are mainly released when the membrane integrity is lost during hepatocyte necrosis 
and necroptosis. Hepatocyte death can be caused by apoptosis, necrosis, or necroptosis in response 
to diverse liver injuries, and the most common type of hepatocyte death is apoptosis. Hepatocyte 
apoptosis is the characteristic of liver injury and intrahepatic inflammation. Ballooning 
hepatocytes are a histological feature of apoptotic liver cells in NASH27. The death receptor Fas-
FasL, death receptor 5, caspase 8, and mitochondria have been shown to be involved in hepatocyte 
apoptosis28-30. It is induced by multiple insults, including hepatitis virus infection and alcohol 
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consumption, and occurs in NAFLD and cholestatic diseases31. Carbon tetrachloride (CCl4) and 
paracetamol induce hepatocyte necrosis, which is characterized by cell swelling, increased cell and 
organelle membrane permeability, and leakage of intracellular contents and inflammatory factors, 
including DAMPs, interleukin 33 (IL-33), TNFα, IL-6, and CCL2. These factors target 
neighboring or surrounding cells to induce liver inflammation27, which plays a critical role in liver 
fibrogenesis. Hepatocyte swelling is mediated by mitochondrial dysfunction, calcium ion elevation, 
and adenosine triphosphate exhaustion. Hepatocyte necrosis is a predominant inducer of liver 
failure and an effective suppressant of liver regeneration32. Hepatocyte necroptosis is controlled 
necrosis. Alcohol, paracetamol, and TNF-mediated damage induce hepatic necroptosis in the liver. 
Intrahepatic lipid loading along with cell death is a unique feature of necroptosis. Upregulation of 
receptor interacting serine/threonine protein kinase 3 (RIP3) in response to NASH is important for 
the induction of necroptosis signaling33. Depending on the injury type, hepatocyte death occurs 
via the apoptosis, necrosis, or necroptosis pathway. Apoptotic and necrotic hepatocytes release 
ROS, DAMPs, apoptotic bodies, and necrotic fragments, which activate hepatic macrophages and 
HSCs to promote liver fibrosis during the initiation and perpetuation phases of liver injury34 35. 
During the perpetuation phase, non-parenchymal cell activation leads to increased hepatocyte 
death that prolongs liver injury. Activated HSCs and hepatic macrophages release chemokine (C-
X-C motif) ligand 1 (CXCL1), CXCL2, CXCL8, and IL-1β to attract neutrophils that secrete ROS 
and proteases to cause hepatocyte necrosis. Another mechanism of liver injury perpetuation is 
hypoxia due to blood flow interruption, ischemia, and ECM deposition. Hypoxia induces the death 
of hepatocytes surrounded by fibrous tissue and leakage of DAMPs34 36. In addition to releasing 
ROS and cell debris, hepatocytes mediate ECM remodeling by secreting MMPs and TIMPs. 
During the resolution phase, liver regeneration mainly involves two cell populations. Hepatocytes 
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repopulate to compensate for the lost liver mass and function, and HSC activation mediates ECM 
remodeling and repair. Liver regeneration is driven by multiple mechanisms: local hepatocyte 
proliferation to replace neighboring dead hepatocytes in response to trivial liver damage; 
hypertrophy of healthy hepatocytes if less than 10% of the liver cells are impaired; extensive 
hepatocyte mitosis if more than 10% liver cells are damaged; and activation of hepatic progenitor 
cells to supplement hepatocyte repopulation if the liver is severely damaged37-39. Cholangiopathies, 
which lead to cholestatic liver fibrosis, are the main indication for liver transplantation in up to 80% 
of children with liver diseases and in approximately 20% of adult patients40. The main target of 
cholangiopathies is cholangiocytes, which proliferate, secrete inflammatory cytokines, and 
mediate biliary apoptosis and liver fibrosis in response to cholestatic liver injury41. 
 
Macrophages 
Liver macrophages include residential Kupffer cells and monocyte-derived macrophages. The 
former physiologically self-renew and are non-migratory phagocytes. They reside in hepatic 
sinusoids and have high phagocytic capability to maintain liver homeostasis by recognizing, 
ingesting, and degrading pathogens or cellular debris20. Liver insults activate Kupffer cells to 
secret inflammatory mediators, which in turn attract circulating monocytes to infiltrate into the 
liver. Activation of Kupffer cells and recruitment of monocytes are the key steps in liver fibrosis 
initiation and progression. Kupffer cells release cytokines and chemokines to induce the 
conversion of circulating monocytes to numerous monocyte-derived macrophages. The circulating 
Ly-6Chi and Ly-6Clo monocytes originate from the bone marrow or spleen, respectively, and each 
of them expresses specific receptors. Liver injury-induced chemokines such as CCL2 attract Ly-
6Chi monocyte infiltration from the circulation as they express C-C chemokine receptor type 2 
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(CCR2). In addition, phagocytes can infiltrate from the peritoneal cavity and specifically express 
GATA6 transcription factor42. The phenotypes of Kupffer cells and monocyte-derived 
macrophages adapt to the hepatic microenvironment43-45. Macrophage polarization is defined in 
vitro by M1 and M2 macrophage subsets. In response to different stimulators, Kupffer cells and 
infiltrating macrophages either undergo M1 or M2 activation during the initiation and progression 
of liver fibrosis. Classic M1 activation mediated by lipopolysaccharide (LPS) or interferon γ shows 
a pro-inflammatory phenotype by releasing mediators, including TNF-a, IL-6, and IL-1β, whereas 
the alternate M2 activation by IL-4 or IL-10 exhibits an anti-inflammatory phenotype by secreting 
IL-4, IL-10, TGFβ1, and IL-13 (Figure 1.2)20 46. M1 macrophages induce hepatic steatosis, 
hepatocyte apoptosis, and inflammation through these inflammatory cytokines, whereas M2 
macrophages mediate wound repair and fibrogenesis. In the liver, the balance of M1 and M2 
macrophages is pivotal in hepatic pathogenesis and can be regulated by multiple mediators. IL-10 
secreted by M2 macrophages induces M1 macrophage apoptosis to prevent hepatic steatosis and 
liver damage in mice with ALD and NAFLD47. The phenotypes of liver macrophages in vivo are 
more complicated than this binary classification. In the resolution phase of liver fibrosis, an 
additional macrophage phenotype that expresses mixed markers of M1 and M2 macrophages 
promotes HSC apoptosis48.  
 
The heterogenic phenotypes of liver macrophages are rapidly altered and switched in response to 
a myriad of insults. In acetaminophen-induced liver injury, macrophages express both 
inflammatory and resolution markers49. Various insults activate macrophages, resulting in their 
secretion of cytokines and chemokines, which in turn causes monocyte infiltration to augment the 
number of macrophages in the liver. Monocyte-derived macrophages perform distinct functions, 
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depending on the stage of injury. In addition, microRNAs are another group of mediators that 
regulate the balance of M1/M2 macrophages. For example, micr-155 directly targets and 
downregulates IL-13Ra1 and several IL-13-related genes on M2 macrophages and promotes 
classic M1 activation50. Thus, microRNAs can exacerbate injury or provoke tissue repair events. 
Overall, the central function of macrophages is to mediate hepatocyte injury, advance 
inflammation, and activate HSCs to induce fibrosis or promote resolution by releasing specific 
cytokines and chemokines.  
 
Figure 1.2  The activation of M1 and M2 Kupffer cells.  
Sato K, Hall C, Glaser S, Francis H, Meng F, Alpini G. Am. J. Pathol. 2016 
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Myofibroblasts 
Excessive ECM accumulation is a key characteristic of liver fibrosis, and the major cellular source 
of ECM is hepatic myofibroblasts, which consist of a heterogeneous population of liver fibrogenic 
cells. They mainly originate from resident mesenchymal cells of activated HSCs and portal 
fibroblasts. Extrahepatic precursors, including bone marrow-derived cells and circulating 
fibrocytes, are the minor contributors. Whether myofibroblasts are derived from epithelial or 
endothelial cells through EMT or endothelial–mesenchymal transition (EndoMT), respectively, is 
still debated (Figure 1.3)51. The variety of etiologies and different hepatic fibrotic sites might 
determine the contribution of myofibroblasts from distinct origins. A common characteristic of 
HSCs and portal fibroblasts is the production of fibrillar collagens, which represent the main 
components in the ECM. Vitamin A is contained in HSCs, but not in portal fibroblasts. Phenotype 
analysis showed that HSCs are the main cellular source of myofibroblasts in hepatotoxic liver 
fibrosis. Portal fibroblasts are the major contributors of myofibroblasts in early cholestatic liver 
injury, whereas HSCs become the main source in late-stage cholestatic liver disease52. In 
hepatotoxin-induced liver injury, HSCs produce more than 80% of the myofibroblasts53. HSCs are 
the first recognized fibrogenic cell population; in the normal liver, they are quiescent mesenchymal 
cells, rich in lipid droplets containing retinoid (vitamin A), expressing glial fibrillary acidic 
proteins (GFAPs) and adipogenic genes, and residing in the Disse space between hepatocytes and 
sinusoidal endothelial cells54. Therefore, quiescent HSCs are characterized by peri-sinusoidal 
location and vitamin A and GFAP staining. Various liver injuries induce the activation of HSCs 
and their adoption of fibrotic phenotype; HSCs are the main contributors of myofibroblasts. The 
trans-differentiation of quiescent HSCs to myofibroblasts is induced by a group of fibrogenic 
factors in response to various liver injuries. Myofibroblasts attain a fibrotic phenotype through the 
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expression of specific fibrogenic markers such as α-smooth muscle actin, reducing GFAP and 
adipogenic gene expression, and losing vitamin A and lipid droplet content. Activation of HSCs 
comprises initiation and perpetuation phases. The initiation phase is the pre-inflammatory stage, 
in which HSCs undergo transcriptional changes mainly in response to paracrine cytokines, lipid 
peroxide, or stimuli released by injured hepatocytes, infiltrated and activated Kupffer cells, 
endothelial cells, and platelets. Perpetuation is the maintenance stage of the activated HSC 
phenotype and leads to fibrosis regulated by paracrine and autocrine cytokines or growth factors. 
HSCs migrate toward the inflammatory sites via platelet derived growth factor (PDGF), CCL2, 
and CXCR3 chemotaxis. HSC proliferation is mediated by PDGF, vascular endothelial growth 
factor (VEGF), and other mitogens, which increases the HSC cell number to promote fibrosis. 
TGFβ1 and connective tissue growth factor (CTGF) are the two potent fibrogenic factors that 
induce the generation of ECM, including collagen types I and III, fibronectin, and proteoglycans. 
The alpha-smooth muscle actin (α-SMA) is a cytoskeletal protein and the hallmark of 
myofibroblasts, which acquire contractility from increased α-SMA expression. HSC contractility 
relies on calcium signaling as well as endothelin-1 and nitric oxide55. The balance of matrix 
production and degradation is the key event in matrix remodeling to maintain fibrosis. The MMPs 
can degrade both collagen and non-collagen components of the ECM. The TIMPs inhibit MMP 
activity by binding to them. The fibrotic phenotype of activated HSCs is maintained through 
complicated processes, including chemotaxis, proliferation, fibrogenesis, matrix degradation, and 
contractility.  
 
Portal fibroblasts, which are also liver-resident mesenchymal cells, are another source of liver 
fibrogenic cells. In cholestatic and biliary liver diseases, portal fibroblasts trans-differentiate into 
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myofibroblasts and are the main cellular sources of myofibroblasts in the early phase of cholestatic 
fibrosis development. The trans-differentiation of portal fibroblasts also contributes to the 
formation of peri-portal fibrotic septa associated with chronic liver injury. Activated HSCs and 
portal myofibroblasts share some fibrotic markers such as α-SMA and collagens, but also express 
distinct markers. During the differentiation of HSCs to myofibroblasts, target gene expression is 
regulated by transcription factor activation or transcriptional suppression, and post-transcriptional 
regulation is altered by epigenetic modifications, including microRNA regulation, DNA 
methylation, and histone acetylation56. Activated HSCs specifically express desmin, cytoglobin, 
and synaptophysin, and portal myofibroblasts are characterized by IL-6, fibulin-1, and elastin. 
Both activated HSCs and portal myofibroblasts have common fibrotic functions, although portal 
myofibroblasts have superior proliferation potential and higher resistance to apoptosis than 
activated HSCs. Bone marrow transplant studies indicated that bone marrow stem cells and 
circulating fibrocytes are the minor contributors of myofibroblasts. Previous in vitro studies 
suggested that TGFβ induces hepatocytes and cholangiocytes to differentiate into a mesenchymal 
phenotype with fibroblast-specific protein 1 (FSP-1) expression via EMT57. However, in vivo cell 
fate mapping studies showed that epithelial and mesenchymal markers do not co-localize in injured 
livers58 59. All myofibroblasts are effector cells of liver fibrogenesis characterized by fibrillar 
collagen-rich ECM production and have the ability to migrate, proliferate, and contract. In 
response to numerous fibrogenic factors, including cytokines and growth factors, from injured 
liver, hepatic myofibroblasts proliferate, migrate to the injury sites, and accumulate there. 
Subsequently, hepatic myofibroblasts abundantly synthesize and produce a group of ECM proteins 
that mainly consists of fibrillar collagens I and III. Simultaneously, these cells secrete MMPs such 
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as ECM-degrading enzymes, MMP activators, and TIMPs. In chronic liver diseases, ECM 
remodeling is balanced by the secretion of MMPs and TIMPs in response to HSC activation60 61.  
 
Figure 1.3  Heterogeneity of hepatic myofibroblasts.  
Mallat, L. Am. J. Physiol. Cell Physiol. 2013 
 
1.3 TGFβ superfamily signaling in liver fibrosis  
Irrespective of etiology, the common mechanisms of hepatic fibrogenesis include the following 
cellular events: (1) hepatocytes and cholangiocytes undergo apoptosis, necrosis, or necroptosis and 
release ROS and DAMPs, growth factors, cytokines, and chemokines in response to liver injury; 
(2) monocytes, macrophages, and neutrophils are attracted by these factors, migrate to the injury 
sites, and secrete additional growth factors and cytokines/chemokines; and (3) hepatic 
myofibroblasts are trans-differentiated from HSCs, portal fibroblasts, bone marrow-derived cells, 
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and circulating fibrocytes possibly via EMT by a collection of these factors. The pro-fibrotic cells 
possess the properties of high ECM production and deposition, proliferation, migration, and 
contractility. Multiple inflammatory and fibrogenic signaling pathways promote the activation of 
HSCs and portal fibroblasts. TGFβ1 is the major growth factor to activate HSCs and portal 
fibroblasts. PDGF, cytokines (e.g., IL-17, IL-22, and IL-33), chemokines (e.g., CCl2, CXCL2, and 
CXCL10), adipokines (e.g., leptin, adiponectin, and resistin), pro-angiogenic factors (e.g., VEGF-
A and angiopoietin), intracellular signaling, and transcription factors all contribute to this process17 
62.  
 
Figure 1.4  Hepatic TGF-β cellular sources.  
Schon H, Weiskirchen R. Hepatobiliary Surg. Nutr. 2014 
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TGFβ signaling molecules constitute one of the most sophisticated signaling pathways known63-
65. The TGFβ superfamily consists of over 50 secretory, structurally related ligands, which are 
divided into four subfamilies: the TGFβ subfamily, the bone morphogenetic protein (BMP) and 
growth differentiation factor (GDF) subfamily, the activin and inhibin subfamily, and a group of 
various divergent ligands. The majority of TGFβ superfamily ligands are secreted as active dimers 
that are inhibited by several secreted proteins, including follistatin, except for GDF8 and TGFβ, 
which are secreted as immature or inactive precursors66. TGFβ superfamily ligands bind to two 
transmembrane receptors: type I and type II receptors67 68. Type II receptors include TGFβ receptor 
II (TGFBRII), activin receptor II A (ActRIIA), and ActRIIB. Soluble ActRIIB binds to various 
TGFβ superfamily ligands, including GDF5, GDF8, GDF11, activin A, activin B, activin C, activin 
E, Nodal, BMP2, BMP4, BMP6/7, BMP9, and BMP1069-71. TGFβ signaling pathways have multi-
functional effects and complicated intracellular interacting components. The TGFβ superfamily is 
known to play critical roles in embryogenesis, reproduction, and adult tissue homeostasis. TGFβ 
signaling critically modulates the initiation and progression of fibrosis in several organs, including 
the liver64. Hepatic TGFβ is expressed in diverse non-parenchymal cells, including HSCs, Kupffer 
cells, cholangiocytes, liver sinusoidal endothelial cells, lymphocytes, and liver-resident dendritic 
cells (Figure 1.4). Liver macrophages and HSCs are the two major cellular sources of TGFβ1. 
TGFβ1 stimulates hepatic fibrosis through multiple mechanisms. TGFβ signaling is involved in 
approximately all the stages of liver disease progression, from the initiation of liver injury through 
hepatic inflammation, liver fibrogenesis, cirrhosis, and even hepatocellular carcinoma. The TGFβ 
effect is also context-dependent. Primarily, bioactive TGFβ1 first binds to TGFβ receptor II, and 
then phosphorylates TGFβ type I receptor; next, intracellular events activate Smad2/3 and non-
Smad signaling pathways to initiate or suppress target gene transcription (Figure 1.5)17. Presently, 
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although TGFβ1 have been recognized as pro-fibrotic regulator, clinical trials have shown TGFβ1 
inhibition does not offer preventive or regressive effects on liver fibrosis progression, but, in turn, 
causes severe adverse effects such as inflammation and ontogenesis13. 
 
In TGFβ superfamily, different subfamily ligands generally signal via distinct, but overlapping, 
subsets of receptors and Smads. BMPs bind BMP-type II receptors (BMPR2), ActRIIA, and 
ActRIIB; type I receptors ALK1, ALK2, ALK3, and ALK6; and Smads 1, 5, and 8, whereas TGF-
βs and activins use their respective type II receptor TGFBR2 or ActRIIA and ActRIIB, but share 
the type I receptors ALK4, ALK5, ALK7 and Smads 2 and 372 73. Interaction is known to occur 
between BMPs and TGFβ/activin signaling. In particular, BMP7 is a negative regulator for TGFβ 
signaling74. In developmental biology, activin A synergistically acts with BMP4, basic fibroblast 
growth factor, and Wnt to drive embryonic stem cells to the definite endoderm75 76. In the central 
nervous system, activin B and TGF synergistically induce the proliferation and maturation of 
oligodendrocytes during myelin formation77. In HSCs, the activated target genes of TGFβ1 include 
fibrillar collagen I and III and other ECM genes, which contribute to ECM accumulation and liver 
fibrosis, whereas suppressed target genes consist of MMP transcripts that mediate ECM 
degradation. In hepatocytes, TGF-β1 inhibits growth and division by causing G1 phase cell cycle 
arrest and inducing hepatocyte cell death via the apoptosis response. The cytostatic and apoptotic 
effects of TGFβ1 on hepatocytes are pivotal for liver mass homeostasis and tumor development. 
In addition, TGF-β1 causes the trans-differentiation of hepatocytes to myofibroblasts via EMT78. 
In hepatic tumorigenesis, TGFβ1 might exhibit tumor suppressive effects at the early stages and 
promote tumor progression in the late stages when hepatocytes become resistant to the previous 
suppressive effect.   
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Therefore, the clinical application of TGFβ signaling inhibition is limited by the complex role of 
TGFβ in liver fibrogenesis, carcinogenesis, and immune modulation. Moreover, liver TGFBRII 
knockout only partially prevented liver fibrosis in the CCl4-treated mouse model
79. Even with such 
high structural similarities of 74% conservation of sequence identifies between TGFβ1 and TGFβ2, 
78% between TGFβ1 and TGFβ3, 82% between TGFβ2 and TGFβ3, TGFβ1 and TGFβ2 act as 
pro-fibrotic factors80, whereas TGFβ3 acts oppositely81 82. Ligand-dependent consequences are 
exemplified by BMP7 counteracting TGFβ1 activities during organ fibrosis65 83. Individual 
investigations of TGFβ superfamily ligands are required for determining their roles in organ 
fibrogenesis.  
 
Figure 1.5  TGFβ superfamily canonical Smad and non-Smad signaling pathways. 
 Wharton K, Derynck R. Development 2009 
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1.4 Activins in liver fibrosis  
Activin was discovered approximately 40 years ago; activins are homo- or heterodimers formed 
by four inhibin subunits—inhibin βA, inhibin βB, inhibin βC, and inhibin βE—in mammals84. At 
present, the homo-dimers of activins include activin A, activin B, activin C, and activin E, whereas 
the heterodimers are activin AB, activin AC, activin BC, and activin AE22. The inhibin βA or 
inhibin βB subunit can also form inhibin A or inhibin B protein by dimerization with the inhibin 
α subunit. Inhibins function as antagonists of activins in the reproductive system85. The inhibin βA 
and inhibin βB genes are widely and relatively highly expressed in the reproductive system. 
Activin A and B are essential for inducing mesoderm formation during development and 
stimulating follicle stimulating hormone production in the reproductive system86-88. Inhibin βC 
and inhibin βE are expressed primarily in the liver and are dispensable for development and adult 
homeostasis89. Activin A is a homodimer of inhibin βA–inhibin βA, and activin B is a homodimer 
of inhibin βB–inhibin βB (Figure 1.6)84. Activins A, B, and AB signal through activin receptors II 
and I90, whereas activins C and E might not91. Thus far, two type II receptors (ActRIIA and 
ActRIIB) and three type I receptors (activin receptor like kinase, ALK4, ALK5, and ALK7) have 
been identified for activin A and B. Both activin receptors II and I are single transmembrane serine 
threonine kinase receptors that are shared with other TGFβ superfamily ligands92.  
 
Figure 1.6  Structure of activin as dimers of inhibin βA and inhibin βB subunits.  
Asashima M, Ariizumi T. Zoological Science 1995 
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 Activin A and B act through the activin type II receptor and type I receptor pathways. They bind 
to one of ActRIIA and ActRIIB expressed on target cell surfaces, and the type II receptor then 
interacts with an activin type I receptor. Activin A binds to ALK4 and ALK5, whereas activin B 
might act via ALK4 and ALK7 (Figure 1.7)93 94. Binding of the activin type II receptor to activin 
type I receptor results in the phosphorylation of intracellular domains of activin type I receptor, 
which in turn phosphorylates the intracellular proteins Smad2 and Smad3. These phosphorylated 
proteins bind with Smad4, a common mediator, to form a protein complex that translocates to the 
nucleus to act as a transcription factor to regulate target gene expression and affect cellular 
proliferation, differentiation, or apoptosis95. Furthermore, other Smad-independent intracellular 
signaling events via activins/ActRII/ActRI include p38 MAPK, JNK, and ERK1/296 97. 
Intracellularly, Smad2 interacts with other components in wingless/integratiob-1 (Wnt) signaling 
and the β-catenin pathway98. The ability of activins to signal through canonical Smad signaling, 
Smad-independent transduction, and crosstalk of Smad with other signaling pathways lead to a 
complex signaling behavior. None of the activins has been extensively investigated in liver 
homeostasis and disease. Relatively, activin A is the most studied activin in this regard. Activin A 
is expressed and secreted by hepatocytes and other non-parenchymal cells such as HSCs, 
cholangiocytes, and endothelial cells99-101. Several lines of evidence show that activin A is 
associated with liver regeneration, inflammation, fibrosis, and hepatocellular carcinoma22 90 102-104. 
Notably, activin A inhibits hepatocyte DNA synthesis and proliferation and induces hepatocyte 
apoptosis, indicating that it is a negative regulator of liver homeostasis100 101 105. Furthermore, 
activin A stimulates the activation of in vitro cultured HSCs and induces TGFβ1 production in 
fibroblasts from different organs (lung, kidney, and pancreas). TGFβ1 in turn stimulates activin A 
secretion from fibroblasts. These findings imply that activin A is involved in the hepatic fibrogenic 
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response99 102 106. Activin A can stimulate Kupffer cells to release TNFα and TGFβ1, which then 
can activate HSCs107. Activin A is induced in acute liver injury and blocking activin A ameliorates 
CCl4-induced liver injury
108. Hepatocytes express abundant inhibin βA and relatively low amount 
of inhibin βB in rodent livers99. CCl4 upregulated hepatic inhibin βB expression in acute liver 
injury109. As two structurally related proteins, activin A and activin B share 63% identity and 87% 
similarity, and both bind to the same activin receptors II and I. Moreover, multiple common AP-1 
sites have been identified in the promoters of inhibin βA and inhibin βB. This suggests that activin 
B might mediate liver pathogenesis in a similar manner as activin A84 95 110 111. Recently, activin B 
was shown to activate the ALK2/ALK3/Smad1/5/8 signaling pathway and thus upregulate 
hepcidin expression in the hepatocytes of mice subjected to several inflammatory insults, 
suggesting a role of activin B in mediating the hepatic inflammatory response112. Because of its 
ability to bind multiple type I receptors (ALK2, ALK3, ALK4, and ALK7) to activate both 
Smad2/3 and Smad 1/5/8 signaling pathways, activin B might be considered to possess a broad 
spectrum of biological functions, unlike activin A. Whether activin B plays a role in liver 
fibrogenesis is not yet known. This is the major question addressed in this study.   
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Figure 1.7  Modified schematic representation of activin signaling pathway.  
Werner S, Alzheimer C. Cytokine & Growth Factor Reviews. 2006 
1.5 Objectives of the study 
Based on the literature and our preliminary studies, we measured the mRNA and protein 
expression levels of activin B and A in the liver and blood of patients with human liver fibrosis 
and mouse models of various liver fibrosis. We also delineated the detailed molecular mechanisms 
by which activin B directly stimulates different liver cells, including hepatocytes, macrophages, 
and HSCs, along with the well-known pro-fibrotic regulator TGFβ1 in liver cells. Finally, we 
investigated the effect of the inhibition of activin B and A individually or in combination by using 
specific monoclonal antibodies (mAbs) on liver function and fibrosis in CCl4- and BDL-induced 
liver fibrosis models. We hypothesize that activin B participates in modulating the initiation and 
progression of liver fibrogenesis. To test this hypothesis, we defined the following objectives: 
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1. Determine whether activin B is associated with liver fibrosis in human patients. 
2. Determine whether activin B is associated with liver fibrosis in mouse liver injury and 
fibrosis models. 
3. Determine whether activin B directly acts on hepatocytes, macrophages, and HSCs. 
4. Determine whether activin B modulates the initiation of CCl4-induced liver fibrosis. 
5. Determine whether activin B modulates the progression of CCl4-induced liver fibrosis.  
6. Determine whether activin B modulates the initiation of bile duct ligation (BDL)-induced 
liver fibrosis.   
The outcomes of this study might enable to potentially consider activin B as a novel and critical 
regulator of liver fibrogenesis, providing new mechanistic insight into this pathogenesis. Moreover, 
future studies can be directed to evaluate whether activin B is an effective target for the prevention 
and treatment of liver fibrosis.  
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 MATERIALS AND METHODS 
2.1 Human liver and serum samples 
Human liver and serum samples were provided by the Division of Gastroenterology and 
Hepatology of Indiana University School of Medicine; the study protocol was reviewed and 
approved by the Institutional Review Board. Normal liver samples from healthy volunteers (n = 5) 
or from patients with ESLD with advanced fibrosis or established cirrhosis (n = 8) were obtained. 
Liver samples were collected from the patients with ESLD during their liver transplantation 
procedure. Demographic data, cirrhosis etiology, and other relevant information such as 
medication, alcohol use, and smoking history were obtained at the time of enrollment. Liver biopsy 
(n = 21) and blood samples (n = 44) were collected from patients with non-alcoholic steatohepatitis. 
NASH was staged based on the severity of scarring or fibrosis: F0, no scarring; F1, minimal 
scarring; F2, significant fibrosis; F3, severe fibrosis; and F4, cirrhosis or advanced scarring113. 
Blood samples were harvested from healthy controls (n = 16), heavy alcohol drinkers without liver 
disease (n = 36), and heavy alcohol drinkers with liver disease (n = 15). Liver tissue samples were 
snap frozen in liquid nitrogen. Serum and frozen liver samples were stored at -80 ºC until use. 
2.2 CCl4 liver injury model 
All mouse experiments were approved by the Institutional Animal Care and Use Committee of Eli 
Lilly and Company and Indiana University–Purdue University, Indianapolis. Animals were housed 
in a room with controlled temperature (22 ± 2 °C) and a 12-h light-dark cycle, with ad libitum 
access to food (Diet 2014; Envigo, Indianapolis, IN) and water. C57BL/6 female mice (10–12 
weeks of age; Envigo) received intraperitoneal injection of CCl4 (1:10 dilution in corn oil, 1 ml/kg; 
Sigma Aldrich, St. Louis, MO) once to induce acute liver injury or twice per week for 4 or 10 
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weeks to induce liver fibrosis114 115. Activin A mAb (10 mg/kg; MAB3381; R&D Systems, 
Minneapolis, MN), activin B mAb (50 mg/kg; AB-306-AI005; Ansh Labs, Webster, TX), or 
control mouse IgG were administered twice a week. CCl4 is a widely used toxin that is very 
effective in inducing acute and chronic liver injury. It induces hepatotoxicity, hepatocyte necrosis, 
and eventually centrilobular liver fibrosis with repeated administration. CCl4-induced liver fibrosis 
model in rodents is widely applied in pre-clinical studies owing to its high reproducibility and 
similarity to the mechanism of certain human liver diseases. The pathologic feature of CCl4 liver 
fibrosis animal model is similar to those of toxin-induced human liver fibrosis. The mechanism of 
CCl4-induced liver injury involves many complex reactions
116. Initially, CCl4 is transformed to 
trichloromethyl radical (CCl*3) in the liver by the cytochrome P450 Family 2 Subfamily E Member 
1 (CYP2E1), CYP2B1, CYP2B2, and CYP3A of the cytochrome P450 superfamily 
monooxygenases. Subsequently, the highly reactive CCl*3 induces nucleic acid mutation, protein 
hypomethylation, and lipid peroxidation, leading to protein synthesis reduction and hepatic 
steatosis. CCl*3 is then oxidized to form another highly reactive trichloromethylperoxy radical 
(CCl3OO
*), which can induce lipid peroxidation and polyunsaturated fatty acid destruction. These 
free radical reactions and pro-fibrotic cytokine and growth factor production result in centrilobular 
hepatocyte necrosis, Kupffer cell activation, inflammation, fibrosis, and cirrhosis117.  
2.3 Bile duct ligation liver injury model 
The surgical procedure was performed under sterile conditions, as previously described118. Under 
isoflurane anesthesia, male C57bl/6 mice (n = 6 to 8) were placed on a heat pad; following a 
median abdominal incision or laparotomy, the common bile duct was exposed, isolated, and 
doubly ligated with non-resorbable sutures (polyester 6–0; Catgut, Markneukirchen, Germany). 
Sham-operated mice were subjected to laparotomy with exposure of the bile duct, but without its 
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ligation. The abdominal muscle and skin layers were stitched, and the mice were treated with 
ketoprofen as an analgesic. A common BDL model represents cholestatic fibrosis due to the 
obstruction of the common bile duct to induce peri-portal biliary fibrosis. The mechanism of BDL-
induced liver fibrosis is the reaction of biliary epithelial cells or cholangiocytes to increased biliary 
pressure; the bile acids and other components secrete inflammatory cytokines, leading to 
cholestasis117. BDL-induced liver fibrosis is characterized by proliferation of cholangiocytes, 
upregulation of cholangiocyte-specific marker cytokeratin 19 (CK19), and increased expression 
of fibrogenic markers such as α-SMA, collagen I, and TGFβ1.   
2.4 Alcohol liver injury model 
Ten-week-old C57/B6 male mice were fed ethanol-containing Lieber-DeCarli liquid diet to study 
alcoholic liver disease. The mice were randomly divided into pair-fed and ethanol-fed groups. The 
mice were subjected to chronic feeding for 10 days with ethanol-containing (5%) Lieber-DeCarli 
liquid diet for 10 days plus binge with ethanol (5 g/kg), as described previously119. The animals 
were killed after 3 h. Chronic alcohol consumption induced liver diseases starting with liver 
steatosis and progression to fibrosis and cirrhosis. In the liver, ethanol is mainly metabolized 
through two oxidative pathways120. First, ethanol is oxidized by alcohol dehydrogenases, cytosolic 
aldehyde dehydrogenase 1, and mitochondrial aldehyde dehydrogenase 2 to generate reduced 
nicotinamide adenine dinucleotide121. Second, CYP2E1 and catalase oxidize ethanol to produce 
ROS, which induce hepatocyte damage. These oxidative stress metabolites induced by ethanol 
damage mitochondria and cause hepatocyte necrosis or apoptosis. In addition to oxidative stress, 
another mechanism of alcohol-induced liver fibrosis is peri-central hypoxia resulting from 
increased oxygen consumption. Sustained hypoxia has multiple effects on hepatocyte damage, 
including increased ROS production, impaired mitochondrial lipid metabolism, and hepatocyte 
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cell death122. Lipid synthesis dysregulation is another mechanism of alcohol-induced liver disease. 
Ethanol exposure leads to liver steatosis via the inhibition of sirtuin1 activity and other associated 
molecules, leading to abnormal lipogenesis123. Damaged hepatocytes and activated Kupffer cells 
release cytokines and chemokines to mediate inflammatory response and activate HSCs to 
differentiate into myofibroblasts124. These mechanisms induce hepatocyte apoptosis or necrosis, 
Kupffer cell-mediated inflammation, and HSC activation and differentiation in alcohol-induced 
liver disease. 
2.5 Cell culture 
Primary mouse hepatocytes (PMHs) were isolated and grown from adult male C57Bl/6 mice, as 
described previously125. Briefly, under anesthesia, the peritoneal cavity was opened, and the liver 
was perfused in situ via the portal vein for 4 min at 37 C with calcium-magnesium (CM)-free 
HEPES buffer and for 7 min with CM-free HEPES buffer containing Type IV collagenase (35 
mg/100 mL) and CaCl2 (10 mM). Cells were used only if the cell viability was above 90% as 
assessed by trypan blue exclusion. After three centrifugations (44 g for 2 min) in Leibovitz’s L-15 
washing media supplemented with 0.2% bovine albumin, cells were plated onto 24-well or 96-
well plates (26,000 cells/cm2). Cells were cultured in high-glucose (25 mM) DMEM supplemented 
with 10% FBS. All culture media contained penicillin (100 units/ml) and streptomycin (100 μg/ml). 
After cell attachment for 2 h, the medium was replaced with fresh medium supplemented with 10% 
fetal bovine serum (FBS). PMH cultures were maintained under 5% CO2 atmosphere at 37 C. 
RAW264.7 cells, a mouse macrophage cell line, were purchased from American Type Culture 
Collection (Manassas, VA) and cultured following manufacturer’s manual. LX-2 cells, a human 
hepatic stellate cell line, were cultured in DMEM supplemented with 2% FBS (Gibco, Invitrogen, 
Carlsbad, CA); they were a gift from Dr. Scott L. Friedman from the Mount Sinai School of 
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Medicine (New York, NY). These cells were treated with activin A, activin B, activin C, CXCL1, 
and TGFβ1 (Table 2.1). 
Table 2.1  Proteins used in the in vitro studies 
Protein Catalogue number Vendor 
Activin A 338-AC R & D systems 
Activin B 8260-AB R & D systems 
Activin C 489-AC R & D systems 
TGF β1 7666-MB R & D systems 
CXCL1 453-KC R & D systems 
 
2.6 Smad2/3-binding element reporter assay 
HEK293 cells stably expressing the Smad2/3-binding element (SBE)-12-luciferase system 
(Qiagen) were seeded at 50,000 to 100,000 cells/well/100 µL DMEM/F12 (Invitrogen) containing 
10% FBS into a poly-D-lysine-coated 96-well plate. Following at least 16 h of incubation at 37 C, 
the media was aspirated and replaced with 50 µL of 1% FBS-DMEM/F12. Anti-activin A mAb or 
anti-activin B mAb were serially diluted (1:2) with 1× PBS, pH 7.4 to produce the following 
titration range (3000 ng/mL to 23.4 ng/mL). Each concentration was then mixed with an equal 
volume of 15 ng/mL of activin A or activin B (R&D Systems) and incubated at room temperature 
for 30 min, after which 100 µL of the mixture was added to individual wells. The Smad reporter 
(I.E. 100% signal) was induced by either activin A or activin B alone, and negative controls (I.E. 
0% background signal) were induced by vehicle alone. Plates were incubated at 37 °C for 20 h, 
followed by aspiration, and washed once with 1× PBS. Cells in individual wells were subjected to 
lysis, and luminescence was measured using a GeniosPRO instrument with substrate injection 
(Luciferase Reporter Gene Assay Kit, Roche). Values shown in the figures are representative of 
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experiments performed in triplicate. Relative luciferase units were measured, and IC50 curves were 
fitted using GraphPad Prism software (GraphPad Software, Inc.). 
2.7 The in-situ hybridization assay  
The cellular source of TGFβ ligands in injured liver tissue was determined by subjecting liver 
sections to in situ hybridization (ISH) for inhibin βA, inhibin βB, and TGFβ1. The in-situ detection 
of these transcripts was performed on paraffin-embedded tissue sections by using the RNAScope 
assay (Advanced Cell Diagnostics). Sections were pretreated using an extended protease treatment 
and hybridized under conditions as described (RNAScope Sample Preparation and Pretreatment 
Guide) by using automated RNAScope probes for activin A, activin B, and TGFβ1, as well as 
standard negative dihydrodipicolinate reductase (DapB; a bacterial gene) and positive 
peptidylprolyl isomerase B (PPIB) control probes (Table 2.2). The probes were detected using 
RNAScope LS 2.5 Duplex brown Assay for the Leica Bond RX auto-stainer (Cat. no. 322440) and 
Brown DAB (Cat. no.DS9800). Slides were counter-stained with hematoxylin. 
Table 2.2  RNAscope probes used in the in-situ hybridization 
RNAscope probe Catalogue number Vendor 
Inhibin βA 455871 Advanced Cell Diagnostics 
Inhibin βB 475271 Advanced Cell Diagnostics 
TGF β1 407751 Advanced Cell Diagnostics 
PPIB 321651 Advanced Cell Diagnostics 
DapB 320759 Advanced Cell Diagnostics 
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2.8 Microarray and quantitative RT-PCR analysis 
Human stellate cells (LX-2 cells) were cultured overnight in six-well dishes at 5 × 105 cells per 
well. The LX-2 cells were then treated with activin A, activin B, or TGFβ1 (R&D System, 
Minneapolis, MN) for 6 h. The RNA was extracted from treated LX-2 cells by using TRIzol 
reagent (Life Technologies, Waltham, MA). Following manufacturer’s instructions, 1 mL of 
TRIzol was added to each cell pellet. Next, 500 µL of chloroform was added and mixed well, and 
then the samples were centrifuged at 12,000 g for 15 min at 4 °C. The aqueous phase was carefully 
removed and transferred to a new tube. RNA was precipitated with 100% isopropanol and 
centrifuged at 12,000 g for 10 min at 4 °C. The supernatant was removed, and the RNA pellet was 
washed with 75% ethanol and centrifuged at 7500 g for 5 min at 4 °C. The pellet was air dried and 
re-suspended in RNase-free water. The absorbance at 260 and 280 nm was measured to determine 
the RNA yield.  
 
Next, 2 µg of total RNAs was reverse transcribed using the High-capacity cDNA Archive Kit 
(Applied Biosystems, Beverly, MA) and then applied to HG-U133 plus 2 chips for microarray 
analysis. For real-time RT-PCR analysis, all cDNAs were assayed for house-keeping genes such 
as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ribosomal protein lateral stalk 
subunit P0 (RPLPO) and genes of interest by using TaqMan Gene Expression Analysis and the 
Assay-On-Demand primer/probe sets (Applied Biosystems, Beverly, MA; Table 2.3). The mRNA 
levels of genes of interest were quantified by determining the cycle number at which amplification 
detection threshold was achieved. Real-time PCR analyses were performed in 10 µL reactions 
according to manufacturer’s guidelines. Triplicate samples were subjected to quantitative PCR by 
using QuanStudio 7 Flex (Applied Biosystems, Beverly, MA) real-time PCR system with the 
maximum cycle number of 40. After the expression was normalized to the housekeeping gene, the 
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expression of the genes of interest was examined in the treated group compared to that in the 
vehicle control or sham group for subsequent analysis.  
 
Table 2.3  Primers/probe sets used for RT-PCR 
Gene Catalogue number Amplicon length (base pair) 
GAPDH Mm99999915_g1 109 
RPLPO Mm00725448_s1 124 
Inhibin βA Mm00434339_m1 65 
Inhibin βB Mm03023992_m1 120 
Inhibin βC Mm00439684_m1 82 
TGF β1 Mm01178820_m1 59 
CTGF Mm01192933_g1 67 
Col1α1 Mm00801666_g1 89 
ACTA1 Mm00808218_g1 134 
Smad3 Mm01170760_m1 59 
IKBKB Mm01222247_m1 63 
TNFα Mm00443258_m1 81 
CCL2 Mm00441242_m1 74 
TWEAK Mm02583406_s1 87 
Fn14 Mm01302476_g1 88 
CXCL1 Mm04207460_m1 111 
iNOS Mm00440502_m1 66 
ACVR1 Mm01331069_m1 65 
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Table 2.3 continued 
CKDNiB Mm00438168_m1 81 
CASP3 Mm01195085_m1 70 
CASP6 Mm01321726_g1 96 
GNDF Mm00599849_m1 101 
SOX4 Mm00486320_s1 94 
CXCR2 Mm99999117_s1 64 
IL-6 Mm00446190_m1 78 
IL-1β Mm00434228_m1 90 
 
2.9 Blood chemistry analysis 
Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), glucose, and total 
bilirubin levels were measured using a Hitachi Modular Analyzer (Roche Diagnostics, 
Indianapolis, IN).   
2.10 ELISA of activin A and activin B 
Liver lysates were generated using 1 mL of lysis buffer per 100 mg liver tissue (Cell signaling 
Technologies, Dancers, MA). The protein concentration of the liver lysates was determined using 
bicinchoninic acid Protein Assay Kit (Thermo Scientific, Waltham, MA)43, which is a standard 
method for colorimetric detection of total protein. Serially diluted bovine serum albumin (BSA) 
was used as a protein standard. The protein concentration was quantified at 570 nm. The same 
amount of total protein of liver lysate samples was treated with 10 mmol/L dithiothreitol in PBS 
for 1 hour at room temperature before plating. Anti-activin A antibody was coated and 
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reconstituted in PBS at a final concentration of 100 mg/mL (AF338; R&D Systems). Anti-activin 
A antibody (100 mL per well) was diluted to 1 mg/mL in coating buffer (SH30256.01; Hyclone, 
Waltham, MA), incubated for 1 hour at 37 °C, and blocked for 1 hour; next, the samples were 
incubated at room temperature for 1 hour. Poly-streptavidin horseradish peroxidase and 3-, 30-, 5-, 
and 50-tetramethylbenzidine block steps were performed, and plates were read at 450 to 630 
nmol/L. The enzyme-linked immunosorbent assay (ELISA) was validated using purified activin 
A protein. Activin B proteins in the liver tissue, serum, or cell culture supernatants were quantified 
using ELISA (Activin B ELISA kit; Ansh Labs, Webster, TX) according to the manufacturer 
protocol. 
2.11 Histology and immunohistochemistry  
The livers were preserved in 10% neutral-buffered formalin for 24 h, embed in paraffin, cross-
sectioned at 3 µm, deparaffinized at room temperature, and stained with hematoxylin and eosin 
(H&E). Adjacent 3 µm sections were immunolabeled using heat-induced epitope retrieval 
(HIER)91 and a Dako autostainer. Briefly, sections were deparaffinized at room temperature and 
rehydrated in 1× TBST immediately before HIER treatment by using Biocare Decloaking 
Chamber Pro with DIVA, pH 6 solution (Biocare). The set point 1 was programmed for 125 °C 
for 30 s (20 PSI) and then cooled down to 89.5 °C for 10 s. The slides were removed and slowly 
rinsed with ddH20 for 5 min, and then immediately rinsed several times in 1× TBST. Endogenous 
peroxidase was blocked for 10 min, and endogenous biotins were blocked for 15 min. Additional 
protein block was performed for 30 min before the sections were subjected to commercial anti-
mouse F4/80, MPO, CK19, and Ki67 clone BM8 (Table 2.4) for 1 h. Biotinylated polyclonal rabbit 
anti-rat secondary antibodies (Dako) were applied for 30 min. Next, HRP-labeled streptavidin-
biotin (Dako) was applied for 10 min, and 3-3-diaminobenzidine tetrahydrochloride (Dako) was 
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applied for 5 min; the slides were counterstained with hematoxylin. Negative controls were 
produced by replacing the primary antibodies with purified rat IgG2aK. Immunolabeled slides 
were examined along with H&E-stained slides to relate cell type identification to cytological 
features. Muscle images were acquired using a digital camera (Spot Digital Camera; Diagnostics 
Instruments, Inc.) and associated software (Spot Advanced) attached to an upright light 
microscope (Leica DM5000B) at 20× magnification.   
 
Table 2.4  Antibodies used in immunohistochemistry 
Antibody Catalogue number Dilution Vendor 
MPO AF3667 1:500 R & D systems 
F4/80 14-4801-82 1:500 eBioscience 
CK19 ab133496 1:500 Abcam 
Ki67 RM-9106 1:200 Thermo Fishers Scientific 
 
2.12 Statistical analysis 
All data are expressed as mean ± standard error of the mean. Significance of differences among 
group means was determined using ANOVA or Dunnett’s tests, followed by two-tailed unpaired 
Student’s t-test. Statistical significance is considered at P < 0.05. GraphPad Prism Software was 
used for data analysis and figure preparation.  
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 ACTIVIN B MEDIATES HEPATIC FIBROSIS 
3.1 Introduction 
Liver fibrosis is the common consequence of liver injury secondary to ALD, NASH, viral hepatitis, 
and autoimmune liver disease126. The initiation and progression of liver fibrosis are driven by 
complicated cellular and molecular mechanisms11 127-129. Damaged hepatocytes and cytokines 
released from inflammatory cells such as Kupffer cells can directly or indirectly activate the 
conversion of HSCs to myofibroblasts, leading to the accumulation of collagen I and III and other 
ECM components as well as liver fibrosis62 126 130.  
 
Activins are dimers formed by four inhibin subunits—inhibin βA, inhibin βB, inhibin βC, and 
inhibin βE—in mammals84. Widely expressed inhibin βA and inhibin βB genes are essential for 
inducing mesoderm formation during development and follicle stimulating hormone production in 
the reproductive system86-88. Inhibin βC and inhibin βE are expressed predominantly in the liver 
and are dispensable during development and for maintenance of adult homeostasis89. Activin A, 
B, AB, C, and E represent homo- or hetero-dimers of inhibin βAβA, βBβB, βAβB, βCβC, and 
βEβE, respectively84. Activin A, B, and AB signal through activin receptors/Smad2/3 pathway, 
whereas activin C and E might not91. Activin A is expressed and secreted by hepatocytes and non-
parenchymal cells such as HSCs, cholangiocytes, and endothelial cells in the liver99-101. Several 
lines of evidence show that activin A is associated with liver regeneration, inflammation, fibrosis, 
and hepatocellular carcinoma22 90 102-104. Notably, activin A inhibits hepatocyte DNA synthesis and 
proliferation and induces hepatocyte apoptosis, which indicates that it is a negative regulator for 
liver homeostasis100 101 105. Furthermore, activin A stimulates the activation of cultured HSCs, 
implying its involvement in the hepatic fibrogenic response99 102 106. It also stimulates primary 
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Kupffer cells to release TNFα and TGFβ1, which activate HSCs107. Activin A production is 
induced in acute liver injury, and neutralization of activin A has been shown to reduce CCl4-
induced liver injury in mice108. 
 
 As a structurally close protein, activin B shares 63% identity and 87% similarity to activin A84. 
Both ligands bind to the same activin receptors II and I, and multiple common AP-1 sites in the 
individual promoters of both inhibin βA (subunit of activin A) and inhibin βB (subunit of activin 
B) have been identified, suggesting that activin B might share similarities to activin A with regard 
to the mediation of liver pathogenesis84 95 110 111. Hepatocytes constitutively express abundant 
inhibin βA, but relatively low level of inhibin βB99. However, hepatic inhibin βB expression is 
highly upregulated in CCl4-induced acute liver injury
109. Recently, activin B was shown to 
upregulate hepcidin expression in hepatocytes via Smad1/5/8 signaling in response to several 
inflammatory insults in mice. This finding suggests that activin B is involved in mediating hepatic 
inflammatory response112. However, whether activin A, especially activin B, can mediate liver 
fibrogenesis is not yet known. This study aimed to determine the role of activin B and its 
mechanism in liver fibrosis.   
3.2 The levels of hepatic and circulating activin B significantly increase in patients with liver 
fibrosis 
First, we determined whether activin B and A are clinically relevant to different etiologies of liver 
fibrosis. With regard to mRNA expression, inhibin βA represents activin A, and inhibin βB 
symbolizes activin B as activin A and activin B are the homodimers of inhibin βAs and inhibin 
βBs, respectively. We found that, in patients with advanced liver fibrosis or cirrhosis, hepatic 
activin B mRNA and protein were markedly increased relative to those in healthy controls (Figures 
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3.1A&B). Circulating activin B did not increase in excessive alcohol users without liver disease 
but showed more than five-fold elevation in patients with alcoholic cirrhosis (Figure 3.1C). In 
patients with NASH, the hepatic and serum levels of activin B significantly increased only in those 
with F4 fibrosis, but not in those of the F0 and F1 groups (Figures 3.1D&E). In addition, we found 
that the serum level of activin A markedly increased in individuals with F1 fibrosis. Thus, we 
showed that the expression of activin B is correlated with advanced fibrosis/cirrhosis, irrespective 
of the underlying disease etiologies.  
A                                                                   B                           
 
 
 
 
Figure 3.1  Liver and serum activin B levels increase in patients with liver fibrosis. 
(A) The mRNA expression of hepatic inhibin βA and inhibin βB in patients with ESLD (n = 8) 
and healthy controls (n = 5) was analyzed using qRT-PCR. (B) Protein expression of hepatic 
activin A and activin B in patients with ESD (n = 8) and healthy controls (n = 5) was quantified 
using ELISA. (C) The concentrations of serum activin A and activin B proteins were determined 
using ELISA in healthy controls (HC; n = 16), heavy drinkers without liver diseases (HD; n = 
36), and heavy drinkers with liver disease (HD + LD; n = 15). Activin A and activin B proteins 
were evaluated using ELISA in the livers (D) and serum (E) of patients with different stages of 
NASH (F0: n = 4, F1: n = 6, F3: n = 4, and F4: n = 6). For all the above assays, data are 
expressed as means ± S.E.M. *, P < 0.05 compared to healthy controls or the F0 group. 
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Figure 3.1 continued 
C                                                                    D 
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3.3 Hepatic and circulating activin B levels are elevated in mouse models of CCl4-induced acute 
liver injury and liver fibrosis  
To further investigate the expression pattern and cellular sources of activin B and A in liver injury, 
we performed acute and chronic liver injury studies in mice. In an acute model after the single 
administration of CCl4, we found significant upregulation of hepatic inhibin βB mRNA expression 
up to 3 days after injection (Figure 3.2A), concomitant with the increase in hepatic activin B 
protein concentration (Figure 3.2B). In addition, we found an increase in serum activin B protein 
at 6 and 24 h after injection (Figure 3.2C). Unlike activin B, hepatic mRNA and protein 
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concentrations and serum levels of activin A increased only at 24 h after CCl4 injection (Figures 
3.2D–F). We used mouse liver fibrosis model with CCl4 injection for 4 weeks and ALD model of 
chronic alcohol plus binge to determine the levels of activin B in hepatic fibrogenesis and chronic 
liver injury. In the CCl4 model, only the mRNA expression and serum levels of activin B increased, 
but not of activin A (Figures 3.2G&H). Similar findings were found in mice fed chronic alcohol 
plus binge model (Figures 3.2J&K). The cellular sources of activin B were revealed using ISH. 
Activin B was mainly transcribed in the hepatocytes and biliary epithelial cells of livers in vehicle 
controls as well as in fibrogenic cells in the mice with fibrotic livers (Figure 3.2I). We concluded 
that, in CCl4-induced liver injury, activin B is persistently associated with liver disease progression 
from the acute to chronic phase, whereas activin A is transiently relevant to the acute phase.  
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Figure 3.2  Liver and serum activin B levels increase in mouse acute liver injury and chronic 
liver fibrosis models induced by CCl4 administration.  
(A) The mRNA expression of hepatic inhibin βB was analyzed using qRT-PCR at the indicated 
time points after single CCl4 or vehicle administration in mice (n = 6). (B&C) Activin B protein 
was quantified using ELISA in the livers (B) and serum (C) at 6 and 24 h after single CCl4 or 
vehicle administration in mice (n = 8). (D) The mRNA expression of hepatic inhibin βA was 
analyzed using qRT-PCR at the indicated time points after single CCl4 or vehicle administration 
in mice (n = 6). (E&F) Activin A protein was quantified using ELISA in the livers (E) and 
serum (F) at 6 and 24 h after single CCl4 or vehicle treatment in mice (n = 8). (G–I) After CCl4 
or vehicle was administered twice per week for 4 weeks in mice, (G) mRNA expression of 
hepatic inhibin βA and inhibin βB was assessed using qRT-PCR (n = 10); (H) concentrations of 
serum activin B protein were quantified using ELISA (n = 10); (I) inhibin βA-, inhibin βB-, and 
TGFβ1-expressing cells were visualized using in situ hybridization on liver sections by using 
mouse inhibin A and inhibin B RNAscope probes and a 2.5 HD Assay-Brown kit. (J&K) Ten 
days after oral alcohol administration in mice, (J) hepatic inhibin βA and inhibin βB transcript 
levels were determined using qRT-PCR (n = 7), and (K) hepatic activin A and activin B protein 
contents were quantified using ELISA (n = 7). For all above quantitative assays, data are 
expressed as means ± S.E.M. *, P < 0.05 relative to vehicle controls.  
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Figure 3.2 continued 
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3.4 Hepatic and circulating activin B levels are elevated in mouse models of BDL-induced acute 
liver injury and liver fibrosis  
To determine whether the increase in activin levels in liver fibrosis and acute live injury models is 
a generalized event or liver disease etiology-dependent, we measured the levels of the two activin 
ligands in another mouse liver injury model. Within one day (the acute phase) after BDL surgery, 
a surgical approach to induce cholestasis-mediated liver injury, we noted persistent increase in 
activin B protein and transient increase in activin A protein in the circulation (Figures 3.3A&B). 
Two weeks after BDL when the livers became fibrotic, activin B, but not activin A, mRNA 
expression was elevated in the livers and protein expression was elevated in the blood (Figures 
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3.3C&D). The ISH results showed that inhibin βA, inhibin βB, and TGFβ1 transcription was active 
mainly in the hepatocytes and biliary epithelial cells of sham controls and in the fibrogenic cells 
of mice with fibrotic livers (Figure 3.3E). We found that, in BDL-induced liver injury, activin B 
is persistently associated with liver disease progression from the acute to chronic phase, whereas 
activin A is transiently relevant to the acute phase.  
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Figure 3.3 Liver and serum activin B levels increase in BDL-induced acute liver injury and 
chronic liver fibrosis mouse models.  
(A and B) Protein quantification of activin A and activin B in the serum at 6 and 24 h after BDL 
surgery. (C) RT-PCR of activin A and activin B in the liver tissue at 2 weeks of BDL surgery. 
(D) Serum activin A and activin B levels in the serum at 2 weeks after BDL surgery. (E) Inhibin 
βA-, Inhibin βB-, and TGFβ1-expressing cells were visualized using in situ hybridization on 
liver sections by using mouse inhibin βA and inhibin βB RNAscope probes and a 2.5 HD Assay-
Brown kit. Data are expressed as means ± S.E.M. Significance is indicated at *P ≤ 0.05, treated 
group vs. vehicle group (Dunnett’s one-way ANOVA). 
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3.5 Hepatic activin B levels are elevated in the ALD mouse model  
Next, we determined activin B and activin A levels in the alcoholic liver fibrosis model. After 
mice were fed alcohol for 10 days, both mRNA and protein expression of activin B, but not of 
activin A, was upregulated in the liver (Figures 3.4A&B). Thus, we showed that, irrespective of 
liver injury types, activin B is persistently associated with liver disease progression from the acute 
to chronic phase, whereas activin A is transiently relevant to the acute phase. Moreover, the 
association of activin B with chronic liver injury is highly conserved between humans and mice.  
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A                                                                    B 
   
Figure 3.4  Liver activin B level increases in the alcohol-induced liver injury mouse model.  
(A) Hepatic inhibin βA and inhibin βB transcript levels were determined using qRT-PCR (n = 7), 
and (B) hepatic activin A and activin B protein contents were quantified using ELISA (n = 7). 
For all the above quantitative assays, data are expressed as means ± S.E.M. *, P < 0.05 relative 
to vehicle controls. 
3.6 Activin B and A are associated with hepatocyte injury and might induce hepatocyte 
differentiation 
The ISH results showed that hepatocytes are the main cellular sources in the liver that express 
inhibin βA and inhibin βB mRNAs (Figures 3.2I&3.3E). To determine whether activin A and B 
proteins are secreted by hepatocytes and how these proteins respond to hepatocyte injury, we 
exposed PMHs to CCl4 or LPS. We found that CCl4 damaged these cells, induced necrosis, and 
elevated ALT and AST in culture supernatants (Figures 3.5A&B) as well as activin A and B 
protein levels (Figure 3.5C). Cell viability was marginally, significantly, and additively improved 
by neutralizing activin A, activin B, and their combination in PMHs, respectively (Figure 3.5D). 
In contrast, LPS only stimulated PMHs to increase activin A production without affecting activin 
B, ALT, and AST (Figure 3.5C). These data suggest that hepatocytes are one of the cellular sources 
responsible for the secretion of activin B, and activin A exhibits toxin-dependent responses. 
Moreover, activin B production in hepatocytes was accompanied by hepatocyte injury and cell 
death. Notably, the two activins modulate hepatocyte injury, as neutralization of these proteins 
improved cell viability following insults. We also found that PMHs responded to individual or 
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combined exogenous treatment of these two proteins by uniformly upregulating the transcription 
of TGFβ1, CTGF, and Col1α1, as well as by variously regulating the mRNA expression of ACTA1, 
Smad3, and IKBKB (Figure 3.5E). These genes are associated with myofibroblast activity, 
suggesting that activin A and activin B might be involved in the differentiation of hepatocytes into 
myofibrolast-like cells following injury. Thus, these results suggest that activin B and A have 
redundant, specific, and interactive actions in hepatocytes 
 
A                                                                  B 
 
Figure 3.5  Activin A and B are produced in PMHs and induce differentiation of these cells. 
 Primary hepatocytes were isolated from adult male mice and cultured overnight. Subsequently, 
the cells were treated with vehicle (corn oil), lipopolysaccharide (LPS, 10 µg/mL), or 0.5% CCl4 
for 24 h. (A) Cell viability, (B) supernatant ALT and AST, and (C) supernatant actin A and 
activin B proteins were analyzed. (D) Cell viability of primary hepatocytes after 24-h treatment 
with 0.5% CCl4 and co-treatment with IgG, anti-activin A antibody, and anti-activin B antibody, 
or the combination of anti-activin A and B antibodies at 100 ng/mL each. (E) The mRNA levels 
of the indicated genes were evaluated using real-time RT-PCR in PMHs after treatment with 
activin A and activin B (100 ng/mL each), or their combination, for 24 h. For all the above 
assays, data are expressed as means ± S.E.M. *, P < 0.05 vs. vehicle controls.  
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Figure 3.5 continued 
C                                                                    D 
 
E 
 
 
3.7 Activin B and A directly target macrophages and modulate inflammatory cytokines 
Immune cells centrally mediate inflammation largely by regulating cytokine production. To 
understand how activin B and A regulate inflammatory responses in macrophages, we exposed 
RAW264.7 cells to activin B and/or activin A and evaluated the expression of inflammatory 
cytokines or chemokines. We found that treatment with individual or combination of both ligands 
exerted similar potency in upregulating TNFα, CCL2, TWEAK, and Fn14 expression (Figure 
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3.6A), indicating that activin B and A might have redundant actions on macrophages. Notably, 
treatment with individual ligands equally, whereas treatment with both ligands additively, elevated 
CXCL1 transcript level, coincident with inducible nitric oxide synthase (iNOS) activation only 
after exposure to both ligands (Figure 3.6A). This suggests that the additive increase in CXCL1 
expression after exposure to both ligands, but not to either of the single ligands, was necessary to 
achieve iNOS activation. To test this, we treated RAW264.7 cells with CXCL1 protein and found 
that CXCL1 upregulated iNOS expression by 30-fold after 24 h of treatment (Figure 3.6B). Thus, 
activin B and A were found to directly target macrophages and additively stimulate sufficient 
production of autocrine CXCL1 to induce iNOS transcription. These data suggest the existence of 
an activin B/activin A/CXCL1/iNOS signaling pathway that modulates macrophage activity, 
further supporting the notion that activin B and A essentially collaborate with each other to activate 
the transcription of a subset of inflammatory cytokines and chemokines.  
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A                                                                                         
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  Figure 3.6  Activin A and B induce macrophages to express inflammatory cytokines or 
chemokines.  
(A) Transcripts of the genes indicated were quantified using qRT-PCR in RAW264.7 cells after 
exposure to activin A (100 ng/mL), activin B (100 ng/mL), or both (100 ng/mL each) for 24 h. 
(B) The mRNA expression of iNOS was evaluated using qRT-PCR in RAW264.7 cells 
following vehicle or CXCL1 treatment for 6 or 24 h. For the above quantitative analyses, data 
are presented as means ± S.E.M. *, P < 0.05 vs. vehicle controls.  
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3.8 Activin B and A directly and coordinately promote HSC activation 
Myofibroblasts centrally drive liver fibrogenesis and are primarily differentiated from activated 
HSCs. The human HSC cell line LX-2 has been widely used to study the function of HSCs. We 
assessed the behavioral response of LX-2 cells to activin A, activin B, their combination, and 
transforming growth factor (TGF)1, a recognized regulator of HSC activity. We found that LX-
2 cells formed a septa-like structure following 24 h of exposure to these three ligands (Figure 3.7A), 
a common behavior observed in HSCs during liver fibrogenesis. This observation suggests that 
activin B and A directly activate HSCs. Based on this finding, we intended to determine whether 
these activin ligands redundantly act on HSCs at the molecular level. Hence, we treated LX-2 cells 
with activin A, activin B, or TGF1 protein for 6 h and profiled their early responsive genes by 
using microarray analysis. We found that these three proteins regulate overlapping, but differential, 
gene networks (Figure 3.7B). The 877 overlapping genes were predominately associated with HSC 
activation and hepatic fibrosis, including upregulated TGF signaling negative feedback 
modulator transmembrane prostate androgen-induced protein (TMEPAI), early growth response 
protein 2 (EGR2), and calcium ion-binding protein matrix gla protein (MGP), and downregulated 
BMP4, dual specificity phosphatase 6 (DUSP6), extracellular matrix glycoprotein TNXB, IL-8, 
and IL-17 receptor C (Figures 3.7C–D). These data suggest that activin signaling redundantly 
dictates a spectrum of HSC properties via multiple ligands, including activin A and B. Conversely, 
each of these individual ligands has a large and unique set of genes associated with critical cellular 
functions. For instance, activin B exclusively decreased cell migration-associated scaffold protein 
Ezrin and calcium-dependent phospholipid-binding protein 3, implying its role in controlling HSC 
migration. These data suggest that activin B is a novel direct regulator of HSCs, and that activin 
ligands distinctly, but coordinately, regulate the transcriptome of HSCs.  
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To gain insight into how activin A and B interactively act on HSCs, we treated LX-2 cells with 
activin A or B alone or in combination and then determined the transcriptional response of a group 
of genes known to regulate HSC activity. We observed four scenarios: (1) ACVR1 and CKDNiB 
equivalently responded to individual ligands (Figure 3.7E); (2) CASP6 solely responded to activin 
A (Figure 3.7E); (3) CASP3, GNDF, and CXCL1 specifically responded to dual ligands (Figure 
3.7F); and (4) CTGF equally responded to individual ligands, but interdependently to dual ligands 
(Figure 3.7F). These results indicate that activin B and A have redundant, unique, and interactive 
effects on HSCs. Taken together, these in vitro data show that activin B and A both redundantly 
and interactively modulated HSCs. 
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Figure 3.7  Activin A and B morphologically and molecularly activate HSCs.  
(A) LX-2 cells were treated with bovine serum albumin (BSA, 100 ng/mL), activin A (100 
ng/mL), activin B (100 ng/mL), their combination (100 ng/mL each), or TGFβ1 (5 ng/mL) for 24 
h and then subjected to 4′,6-diamidino-2-phenylindole (DAPI) staining. (B) LX-2 cells were 
treated with activin A (100 ng/mL), activin B (100 ng/mL), or TGFβ1 (5 ng/mL) for 6 h. Total 
RNAs were isolated and reverse transcribed to cDNA. Microarray analysis was conducted using 
HG-U133 plus 2 chips (n = 6). The pie chart shows the numbers of genes commonly or uniquely 
regulated by individual TGFβ ligands. (C) The top ten signaling pathways revealed by Ingenuity 
canonical pathway analysis of the 877 target genes shared by these three TGFβ ligands. (D) Heat 
map of 20 genes exhibiting the highest magnitude of upregulation or downregulation in response 
to these three TGFβ ligands. (E & F) LX-2 cells were treated with vehicle, activin A (100 
ng/mL), activin B (100 ng/mL), or their combination (100 ng/mL each) for 24 h. The expression 
of these genes was assessed using qRT-PCR. Data are shown as means of fold changes relative 
to vehicle controls ± S.E.M. *, P < 0.05.  
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3.9 Individual or combinational neutralization of activin B and A distinctly ameliorates the 
progression of CCl4-induced liver fibrosis 
The above association studies in humans and mice and in vitro studies strongly suggested that 
activin B and A differently participate in the regulation of liver fibrosis progression, and hence, 
we intended to confirm this notion. Global gene knockouts of these two widely produced activin 
ligands cause developmental defects, reproductive failure, or postnatal death in mice86-88. 
Therefore, we used a neutralizing antibody to systemically inactivate these two proteins and 
subsequently investigated their effects on the initiation of CCl4-induced liver fibrosis. Five 
treatment groups were included: (1) vehicle; (2) IgG + CCl4; (3) anti-activin A antibody + CCl4; 
(4) anti-activin B antibody + CCl4; and (5) combination of both antibodies + CCl4. In the initial 
association studies, we found time windows during which both activin A and B were induced in 
the acute phase of liver injury (Figures 3.2A–F). This co-induction suggested a possible 
spatiotemporal coordination between the two activin ligands, warranting their combined 
application in this study. Antibodies were initially dosed half an hour before the first CCl4 injection 
and were dosed weekly thereafter.  
 
A dosage of 10 mg/kg of anti-activin A antibody weekly was used because our previous study 
showed the greatest efficacy of this regimen in regressing degeneration of injured skeletal muscle 
in mice131. We administered 50 mg/kg as the maximal efficacy dose of anti-activin B antibody 
once per week as the IC50 was found to be five-fold higher than that of anti-activin A antibody, as 
determined by using a SME promoter luciferase assay (Figures 3.8A–D)132, and liver mass 
increased in a mouse homeostasis study (Figure 3.8E). Anti-activin B antibody exerted numerous 
beneficial effects, including reduced liver injury indicated by serum ALT and AST (Figures 
3.8F&G), elevated serum glucose and decreased total bilirubin level (Figures 3.8H&I), and 
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decreased liver fibrosis analyzed using collagen staining and collagen 1α1 mRNA expression 
(Figures 3.8J–L). Anti-activin A antibody treatment reduced liver injury and improved liver 
functions to a lesser extent than anti-activin B antibody, but did not decrease total bilirubin and 
liver fibrosis, although collagen 1α1 mRNA expression was inhibited (Figures 3.9E–J). The dual 
antibodies showed beneficial effects equivalent to, or, in some cases, greater than that of activin B 
mAb alone (Figures 3.8E–J). However, only activin B mAb treatment did not increase the liver to 
body weight ratio (Figure 3.8M). In livers chronically damaged by CCl4, activin B and A are 
essential collaborators to induce CXCL1, because neutralizing either one of them prevented 
CXCL1 upregulation, resulting in prohibited iNOS elevation (Figure 3.8P). In addition, hepatic 
CTGF and TGFβ1 upregulation was completely suppressed by neutralizing either one of the two 
activin ligands in mice chronically treated with CCl4 (Figure 3.8P). CXCL1 has multiple functions, 
one of which is to attract neutrophils to infiltrate the liver injured by alcohol133. However, we 
observed that, in livers chronically damaged by CCl4, myeloperoxidase (MOP)-positive 
neutrophils were concentrated in the septa (Figure 3.8Q). When anti-activin A antibody treatment 
prevented hepatic CXCL1 induction without affecting septa formation, MOP-positive neutrophils 
were still largely located in the septa (Figure 3.8Q). These observations suggest that neutrophils 
are closely associated with liver fibrogenesis, and their infiltration might not be regulated by 
CXCL1 in this setting. When liver fibrosis was largely prevented, neutrophils were overtly reduced 
and diffused (Figure 3.8Q). The distribution of F4/80-positive hepatic macrophages (Kupffer cells) 
was similar to that of neutrophils in all experimental groups (Figure 3.8Q). These data suggest that 
(1) activin B, and to a lesser extent activin A, mediate the initiation of liver fibrosis by promoting 
inflammatory response and fibrogenesis, and (2) activin B inhibition or, even better, both activin 
B and A inhibition prevents liver fibrosis.  
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Figure 3.8  Anti-activin A antibody, anti-activin B antibody, and their combination show distinct 
effects in preventing liver fibrosis induced by CCl4 in mice.  
The Smad2/3 Binding Element (SBE) luciferase assay in SBE-transfected HEK 293 cells to 
determine activin antibody specificity. SBE-transfected HEK293 cells co-treated with activin A 
and activin B antibodies (A), or activin AB (B), activin A (C), or activin C (D) proteins for 24 h. 
Adult female mice were subjected to CCl4 or vehicle injection (i.p.) twice per week for 4 weeks. 
Half an hour before the first CCl4 injection, mice were treated (s.c.) with IgG (60 mg/kg), anti-
activin A antibody (10 mg/kg of anti-activin A antibody + 50 mg/kg of IgG), anti-activin B 
antibody (50 mg/kg of anti-activin B antibody + 10 mg/kg of IgG), or combination of activin A 
and activin B antibodies (10 mg/kg of anti-activin A antibody + 50 mg/kg of anti-activin B 
antibody). Subsequently, antibody treatments were performed once per week. Four weeks after 
the initial CCl4 injection, (E) ALT, (F) AST, (G) glucose, and (H) total bilirubin in the blood 
were analyzed. (I) Representative liver sections stained with Masson trichrome. (J) 
Quantification of the percentage of Masson trichrome staining areas. (K) The mRNA expression 
of hepatic Col1α1 was evaluated using qRT-PCR. (L) Liver-to-body weight ratios. (M–O) Total 
liver RNA samples generated from the experiment described in Figure 3 were subjected to qRT-
PCR analysis for determining the expression of the genes indicated. (P) Immunohistochemical 
analysis of MOP-positive cells (neutrophils), F4/80-positive cells (Kupffer cells), and Ki67-
positive cells (proliferating hepatocytes) on liver sections prepared from the experiment 
described in Figure 3. Data are expressed as means ± S.E.M. (n = 10). *, P < 0.05 compared to 
vehicle controls. #, P < 0.05, compared to IgG controls. 
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3.10 Neutralization of activin B and A regresses CCl4-induced liver fibrosis  
Because of the superior effects of antibody-mediated inactivation of activin B or both activin B 
and A in preventing liver fibrosis, we tested the same strategy to reverse fibrosis in the CCl4 mouse 
model after the disease has been established. Following the same study design as the preventive 
liver fibrosis study, CCl4 was injected twice per week for 10 continuous weeks. Starting at the 
seventh week when liver fibrosis was completely established, antibodies were dosed weekly for 
the remaining 4 weeks. Consequently, we found distinct reversal effects in both the anti-activin B 
and A antibody treatment groups. The reversal effects followed the sequence of the magnitude of 
effect where inactivating both activin B and A had greater effect than inactivating activin B alone, 
and inactivating activin A had the lowest effect. Combinational inactivation exerted the most 
beneficial effects across all assessments, including reduced liver injury (as measured by serum 
ALT and AST), increased serum glucose and total bilirubin level, decreased collagen deposition, 
and less macrophage infiltration (Figures 3.9A–K). Inactivating activin B alone generated a 
stronger anti-fibrotic effect, but nearly equal effects in other assessments, compared with those 
noted after inactivating activin A alone (Figures 3.9A–K). Notably, inactivating activin B alone 
and inactivating both activin B and A equivalently regressed liver fibrosis (Figure 3.9F). 
Neutrophils and Kupffer cells were similarly distributed in fibrotic livers and were concentrated 
in the septa. Neutralizing activin A, activin B, or both did not alter the total number of neutrophil 
infiltrations, but almost equally reduced the total number of Kupffer cells (Figures 3.9H–K). This 
suggests that activin B and activin A essentially cooperate to modulate the functional state of 
Kupffer cells. Taken together, these results suggest that activin B is a stronger driver of liver 
fibrogenesis than activin A, and that these two activin ligands might act cooperatively during the 
progression of chronic liver injury. Moreover, neutralization of either or both ligands might largely 
reverse the already established liver fibrosis, in addition to preventing the onset of disease. 
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Figure 3.9  Anti-activin B antibody, anti-activin A antibody, and their combination show 
different effects in regressing liver fibrosis induced by CCl4 in mice.  
Adult female mice were subjected to CCl4 or vehicle injection (i.p.) twice per week for 10 
weeks. Starting from the seventh week, the mice were treated (s.c.) with IgG (60 mg/kg), activin 
A mAb (10 mg/kg of activin A mAb + 50 mg/kg of IgG), activin B mAb (50 mg/kg of activin B 
mAb + 10 mg/kg of IgG), or the combination of activin A and activin B antibodies (10 mg/kg of 
activin A mAb + 50 mg/kg of activin B mAb) once per week. Ten weeks after the initial CCl4 
injection, (A) ALT, (B) AST, (C) glucose, and (D) total bilirubin in the blood were analyzed. (E) 
Representative liver sections stained with Masson trichrome. (F) Quantification of the 
percentage of Masson trichrome staining areas. (G) Liver-to-body weight ratios. (H) 
Immunohistochemical analysis of MOP-, F4/80-, and Ki67-positive cells on liver sections. 
Quantification of the percentage of MOP- (I), F4/80- (J), and Ki67-positive cells (K). Data are 
expressed as means ± S.E.M. (n = 10). *, P < 0.05 compared to vehicle controls. #, P < 0.05, 
compared to IgG controls. 
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3.11 Individual or combinational neutralization of activin B and A distinctly prevents the 
progression of BDL-induced liver fibrosis 
To further validate the above in vivo findings, we conducted a similar study in mice with BDL-
induced chronic liver injury. Experimental groups included (1) sham control; (2) IgG + BDL; (3) 
activin A mAb + BDL; (4) activin B mAb + BDL; and (5) activin A mAb + activin B mAb + BDL. 
We dosed the first antibody one day before BDL surgery and the second one a week after BDL. 
Endpoint analyses were conducted 2 weeks after BDL. We found that BDL induced the 
upregulation of activin B mRNA expression without affecting activin A and activin C in the liver 
(Figure 3.10A). Individual antibody mildly, but dual antibodies almost entirely, inhibited activin 
B mRNA induction in bile duct-ligated livers (Figure 3.10A). Anti-activin B antibody treatment 
reduced liver injury, improved liver function, and decreased liver fibrosis (Figures 3.10B–G). 
Surprisingly, anti-activin A antibody did not show beneficial effects in nearly all the endpoints 
analyzed except that it ameliorated the total bilirubin index (Figure 3.10E). Remarkably, the dual 
antibodies exerted the most prominent efficacy, manifested by reduced liver injury, improved liver 
functions, and decreased liver fibrosis, but further enlarged the livers compared to those of IgG 
controls (Figures 3.10B–H). BDL typically induces biliary ductal reaction or new bile duct 
formation, which was not overtly affected by these antibodies, as revealed by CK19 
immunostaining (Figure 3.10J). Activin B mAb and combination of both antibodies decreased 
hepatic inflammatory cytokines, CXCL1, IL-6, and IL-1β in the liver, and IL-6, TNFα, and IL-1β 
in the blood, whereas activin A mAb only inhibited serum IL-2 (Figures 3.10K–P). These results 
suggest that, in this model, (1) activin B strongly, but activin A minimally, promotes the 
progression of chronic liver injury; (2) activin B profoundly, but activin A slightly, induces the 
inflammatory response of liver fibrosis; and (3) the presence of activin A enhances the promoting 
actions of activin B, indicating why the dual targeting approach is the most beneficial.   
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Figure 3.10  Anti-activin A antibody, anti-activin B antibody, and their combination exhibit anti-
inflammatory and anti-fibrotic effects in the BDL liver fibrosis model. 
Liver injury marker ALT (A) and AST (B), liver functional marker glucose (C), and total 
bilirubin (D) levels were determined in the serum of all the groups. (E) Representative 
histological images of trichrome staining, and (F) quantitative graph for collagen in all groups. 
(G) Liver index (ratio of liver weight to body weight) and (H) RT-PCR used to measure the 
levels of Col1a1, CTGF and TGFβ1, iNOS, CXCL1, SOX4, CXCR2, IL-6 and IL-1β at 2 weeks 
after BDL surgery after co-treatment with vehicle (mIgG), anti-activin A antibody, anti-activin B 
antibody, and combination of both (n = 8). (I) RT-PCR used to measure the level of activin A, 
activin B, and activin C in all groups. (J) Representative histological images of 
immunohistochemistry and CK19 fluorescence staining. (L and M) Quantification of 
inflammatory cytokines, TNFα, IL-2, and IL-6 in the serum and (N) CXCL1, IL-6, and IL-1β in 
the liver lysates of mice at 2 weeks after BDL surgery.  Data are expressed as means ± S.E.M. 
Significance is indicated as *P ≤ 0.05, treated group versus vehicle group (Dunnett’s one-way 
ANOVA). 
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Figure 3.10 continued 
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3.12 Discussion 
This study mainly aimed to investigate the role of activin B in hepatic fibrogenesis. Our clinical 
and animal studies revealed a correlation between circulating activin B and liver fibrosis severity, 
which indicates that activin B is a potential biomarker and therapeutic target of liver fibrosis. In 
the liver, activin B acts directly on multiple cell populations to induce hepatic fibrogenesis either 
by itself or cooperatively with activin A, especially in HSCs and macrophages. Our study suggests 
that activin B promotes hepatocyte damage and macrophage and HSC activation to induce hepatic 
fibrogenesis by regulating TWEAK/Fn14, CXCL1/iNOS, CTGF, and TGFβ1 multiple signaling 
pathways. Moreover, the inhibition of activin B action remarkably decreased liver injury, 
inflammation, and fibrosis and improved liver function in liver fibrosis mouse models; these 
effects were enhanced when combined with activin A inhibition. The effects of activin B and A 
inhibition on liver fibrosis in animal models open potential clinical therapeutic possibilities for 
patients with liver fibrosis. The primary function of activin A and B is to regulate the reproductive 
system, developmental processes, inflammation, immunity, hematopoiesis, and tumorigenesis. In 
addition to these functions, our findings suggest that activins play a pivotal role in liver fibrosis.  
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The novel roles of activin B in hepatic fibrogenesis other than the reproductive function 
Activins were initially isolated and identified for their roles in regulating developmental and 
reproductive processes. Activin A, a 28 kDa protein, was isolated in 1986 and activin B, a 25 kDa 
protein, was purified in 1992 from porcine ovarian follicular fluid134 135. Both activin A and B 
possess the ability to release follicle stimulating hormone from rat anterior pituitary cells in vitro. 
In developmental processes, activin A plays an important role in embryonic induction, limb and 
nervous system development, and morphogenesis of branched glandular organs and Wolffian duct.  
The involvement of activin A and B in development is also highlighted by the phenotype changes 
in corresponding genetically modulated mice. The phenotype of mice with inhibin βA gene 
knockout is lethal because of the failure in sucking due to mandibular and palate defects and 
absence of coiling in the epididymis86 136 137. Even though mice with inhibin βB gene knockout 
remain alive and fertile, their eye lids are dysfunctional and hence the eyes remain open, resulting 
in permanent ocular damage, and females show prolonged gestation and poor nursing behavior87 
88. In addition, double knockout of inhibin βA and inhibin βB leads to the same defects as those 
noted after individual knockout, without any additional abnormalities86. Knockout of either inhibin 
βA or inhibin βB gene exhibits a distinct phenotype, indicating that each of them has a distinct and 
irredundant function in development. Furthermore, even though activin A and activin B have 
similar actions, their potency varies in developmental and reproductive processes. Activin A is a 
more effective regulatory protein of ovarian and testicular development, whereas activin B is more 
potent to induce embryonic mesoderm formation135 138. In addition, only activin B is involved in 
central nervous system development77 139. All these findings suggest that activin A and activin B 
share certain redundant functions and have some specific functions in developmental and 
reproductive processes, which might extend to other process such as liver fibrosis. 
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The complicated dual roles of activin A in mediating inflammation were shown by in vitro 
monocyte and macrophage studies. At low concentration, activin A induced inflammatory 
cytokines, including IL-1β, IL-6, and TNFα, via the p38 MAPK and ERK1/2 pathways in resting 
monocytes/macrophages, whereas it had inhibitory inflammatory effects in activated macrophages. 
Recently, accumulating evidence shows that activin B is involved in inflammation in acute liver 
injury112 140 141. In mice, activin B mRNA and protein are induced in the liver at 6 hours after the 
administration of LPS, and Kupffer cells and vascular endothelial cells are the main cellular 
sources of activin B140. In cell culture, activin A induced fibroblast proliferation and differentiation 
into myofibroblasts142. It also stimulated TGFβ1 production in renal and lung fibroblasts as well 
as pancreatic stellate cells, indicating that activin A might be a generalized pro-fibrotic regulator 
in multiple tissues143-145. The results of these in vitro and in vivo studies indicate that activin A and 
B might participate in the regulation of inflammation and pathogenesis of liver fibrosis.  
Liver fibrosis is the common consequence of liver injury secondary to various chronic liver 
diseases126. The pathogenesis of liver fibrosis is mediated by complex cellular and molecular 
mechanisms. Herein, we provide the first clinical and experimental evidence suggesting that 
activin B has a functional role in liver fibrosis in initiating liver inflammation and fibrogenesis by 
inducing CXCL1/iNOS in macrophages and CTGF/TGFβ1 in HSCs. In this study, we also showed 
that activin B has substantially similar effects on hepatocytes, macrophages, and HSCs as those of 
activin A, whereas activin B specifically induced a group of genes in HSCs. Moreover, the in vivo 
efficacy results from multiple liver fibrosis mouse models showed that the administration of activin 
B mAb remarkably prevents liver injury and fibrosis induced by CCl4 and BDL, and activin A 
mAb enhanced these preventive effects. The results of our study provide evidence that, in addition 
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to their role in reproductive and developmental processes, activin B and A are involved in liver 
fibrosis.  
 
Activin B is a potential biomarker of liver fibrosis 
Our study identified activin B as a factor closely associated with liver injury, irrespective of 
etiology and species. This reveals a highly conserved, activin B-mediated machinery, which 
fundamentally supports the liver’s ability to respond to various insults in mammals. This 
machinery is activated rapidly following liver injury, operates stably throughout the pathogenesis, 
and predominates until the injured liver becomes fibrotic. We found that activin B mRNA was 
abundantly transcribed in fibrotic cells in chronically injured livers, and hepatic activin B transcript 
expression and protein level were always concomitantly elevated and were correlated with 
enriched circulating activin B. Therefore, increased production of hepatic activin B could largely 
contribute to its systemic enrichment during liver fibrosis development. As activin B is elevated 
both locally as well as systemically in multiple liver fibrosis rodent models and in patients with 
NASH, it is considered a promising biomarker. Further investigations are warranted to potentially 
develop activin B as a reliable and sensitive serum marker for monitoring liver fibrosis progression, 
especially for the diagnosis, staging, and prognosis of liver fibrosis and cirrhosis. The diagnosis of 
liver fibrosis is critical because hepatic fibrosis might progress and ultimately lead to cirrhosis 
with severe complications or hepatocellular carcinoma if the underlying insults persist, and 
management of patients with different stages of liver fibrosis relies on reliable diagnosis. At 
present, liver biopsy remains the gold standard for diagnosis and staging purposes146. Although it 
allows the histological assessment and quantification of liver fibrosis, it has several shortcomings, 
including patient’s unwillingness because of its invasiveness, subsequent pain, and potential 
complications; sampling error; and high cost. These disadvantages limit its repeated application in 
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patients, requiring the exploration of non-invasive and reliable biomarkers of liver fibrosis. In 
addition to liver biopsy, the two other options for diagnosing liver fibrosis are image-based 
assessments and blood tests. Ultrasound-based elastography and magnetic resonance imaging are 
two representative imaging methods for liver fibrosis even though their diagnostic accuracy for 
fibrosis is low147 148. Blood tests might be divided into two classes: class I markers are direct serum 
markers that can be used to measure liver ECM turnover, whereas class II markers are indirect 
serum markers calculated from a mathematical model of liver function change. MMPs, TIMPs, 
collagen IV and VI, hyaluronic acid (HA), and laminin belong to class I biomarkers149 150. 
Collagens and HA are the most widely used markers for evaluating liver fibrosis development. 
The limitations of class I biomarkers are not always correlated with whole tissue function and are 
affected by other factors such as inflammation. Class II biomarkers are cost-effective and include 
ALT, AST, ALP, platelet count, and bilirubin, which reflect liver function, but are not necessary 
for monitoring liver fibrosis151 152. The sensitivity and specificity of these markers can be improved 
by combining diverse serological biomarkers in various degree of complexity. Two representatives 
of combined biomarkers are ALT/AST ratio and AST to platelet ratio index (APRI). Both are 
effective in diagnosing liver fibrosis with relatively high sensitivity in patients with HCV, although 
APRI might not be used in ALD due to the significant platelet suppression of alcohol153 154. 
Nevertheless, these investigations need further exploration, particularly for the detection of 
intermediate fibrosis grades. An ideal non-invasive biomarker is correlated with liver fibrosis 
severity. Activin B is a strong candidate because it is increased in the liver and blood in animal 
models and human patients with liver fibrosis. In particular, hepatic and serum activin B protein 
levels are significantly increased at the F4 stage of NASH (Figure 3.2 D&E). Because of the 
possible direct participation of activin B in hepatic fibrogenesis, this finding provides a new way 
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to explore liver fibrosis biomarkers other than ECM turnover components or liver functional 
enzymes. Future studies need to focus on identifying liver- and serum-correlated soluble proteins 
that are associated with the severity and staging of liver fibrosis. At present, no Food and Drug 
Administration-approved standard medicine is available for liver fibrosis treatment155. The 
promising targets revealed in animal studies encourage scientists to evaluate them in clinical trials. 
However, clinical trials of liver fibrosis are costly, and recruiting patients is difficult as they are 
usually long-term studies that require serial liver biopsies to assess fibrosis progression. Therefore, 
reliable noninvasive markers of liver fibrosis become a key factor to design and monitor clinical 
trials. 
   
Activin B is a novel driver of hepatic fibrogenesis 
Liver fibrosis is a severe health problem as the destruction of the normal liver architecture by ECM 
accumulation and fibrous scar formation along with the loss of functional hepatocytes eventually 
leads to liver failure. At present, no clinically effective therapies are available for liver fibrosis 
except liver transplantation. The potential targets of hepatic fibrogenesis are explored using 
activated HSCs and Kupffer cells as the key fibrogenic effector cells to determine ways to prevent 
its progression and/or induce its resolution. The majority of myofibroblasts are differentiated from 
activated HSCs, and HSC activation is a key step during hepatic fibrogenesis. The molecules and 
pathways required for HSC activation are attracting attention and are investigated as potential 
therapeutic targets. The therapeutic strategy involves suppression of HSC activation, induction of 
activated HSC apoptosis, or manipulation of macrophage activity. In experimental studies, some 
molecules have been shown to be the targets for liver fibrosis. TGFβ1 and hepatocyte growth factor 
(HGF) are representatives of these targets. TGF-β1 promotes HSC activation and proliferation, as 
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well as induces EMT and EndoMT to contribute to myofibroblast populations. However, the 
inhibition of TGFβ1 is ineffective in long-term treatment because of the serious adverse effects 
and complications because of its pleiotropic roles in homeostasis. HGF is a multifunctional 
cytokine involved in hepatic fibrogenesis. In animal models, blocking HGF activity is effective, 
but it increases the risk of carcinogenesis. Therefore, identifying a general target of liver fibrosis 
that is associated with liver fibrosis severity and its blocking has anti-fibrotic effects in multiple 
models is urgently required. 
 
By using both in vitro and in vivo approaches, we showed that activin B is a potent driver of the 
complications (hepatocyte injury, inflammation, and fibrosis) of chronic liver injury. In the liver, 
the initiation and perpetuation of liver fibrosis are controlled by multiple cell populations that 
mainly include hepatocytes, macrophages, and HSCs. We found that activin B mediates hepatocyte 
injury. This is manifested by improved hepatocyte viability and reduced ALT after activin B is 
neutralized in vitro and in vivo. In addition, activin B and A stimulate TGFβ1, CTGF, Col1α1, and 
ACTA1 gene expression in hepatocytes. These activin A- and activin B-induced fibrotic transcripts 
facilitate the trans-differentiation of to a myofibroblast-like phenotype, which provides evidence 
that EMT could be one of the possible sources of myofibroblasts. At the molecular level, we 
revealed some important clues for further mechanistic investigations to understand how activin B 
regulates the activities of macrophages and other immune cells. For example, activin B upregulated 
TWEAK and its receptor Fn14 in macrophages. The TWEAK/Fn14 pathway was shown to 
promote ROS production and oxidative stress in these cells156. TWEAK is known to be primarily 
produced by macrophages and natural killer cells; it induces the expansion of liver progenitor cells, 
mediates the cross-talk among liver progenitor cells/immune cells/HSCs, and eventually augments 
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inflammatory and fibrotic responses in chronically injured livers157-159. This reveals an activin 
B/TWEAK/Fn14 axis operating in multiple liver cell populations in injured livers. Strikingly, we 
showed that activin B is a potent pro-fibrotic factor. It massively altered the transcriptome of HSCs 
in vitro and forced them to form a septa-like structure. Neutralizing activin B alone largely 
repressed septa formation, collagen deposition, and fibrotic gene expression, such as CTGF and 
TGFβ1, in chronically injured liver in vivo. The microarray data provided a list of activin B target 
genes of interest for further studies to elucidate how activin B controls the activities of HSCs. 
Based on these findings and given the persistent increases of hepatic and systemic activin B with 
the progression of liver injuries regardless of etiology and species, we propose activin B as a 
primary and critical factor to sustain the activation of immune cells and HSCs during various 
chronic liver diseases.  
 
Activin B and A are novel and direct regulators of HSCs 
Previous studies have shown that TGF signaling might modulate liver fibrogenesis, for which 
HSCs are central. However, the subset of TGF superfamily ligands that directly target HSCs has 
not been well defined, and whether the ligands activate redundant or distinct TGF signaling in 
these cells remains unclear. We found that TGF ligand, activin B was persistently induced in the 
liver and blood during both CCl4- and BDL-induced chronic liver injury in mice. More remarkably, 
both activin B and activin A proteins stimulated LX-2 cells to form a septa-like structure in vitro, 
similar to TGF1, a mostly studied TGF ligand in liver fibrosis. These findings suggest that 
activin A and B are involved in liver injury progression at least by directly regulating the activities 
of HSCs. To further confirm this at the molecular level, we treated LX-2 cells with activin A, 
activin B, or TGF1 for 6 h and subsequently profiled their early responsive genes by using 
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microarray analysis. We found that these three TGFβ ligands regulate overlapping, but differential 
gene networks, which are associated predominately with HSC activation and hepatic fibrosis and 
with many other HSC activities. Notably, with equivalently high magnitudes, these three TGFβ 
ligands upregulated TMEPAI, apoptosis regulator SOX4, calcium ion-binding protein MGP, and 
EGR2 and down-regulated dual specificity phosphatase 6, BMP4, extracellular matrix 
glycoprotein TNXB, IL-8, and IL-17 receptor C. These data suggest that TGF signaling dictates 
a spectrum of HSC properties independent of its ligands. However, each of these three TGFβ 
ligands targets a unique and large set of genes associated with critical cellular functions. In 
particular, activin A specifically down-regulates solute carrier family 25 member 29, a 
mitochondrial transporter of basic amino acids, suggesting its role in mitochondrial amino acid 
metabolism. Activin B exclusively decreased cell migration-associated scaffold protein Ezrin and 
calcium-dependent phospholipid-binding protein 3, implying that activin B plays a role in HSC 
migration. TGF1 exceptionally suppressed myostatin, a well-established potent inhibitor of 
myogenesis, indicating its possible role in liver–muscle cross-talk. Thus, we showed that (1) 
activin A and B are new regulators of HSCs and thus potentially participate in mediating liver 
fibrogenic responses, and (2) TGF signaling exhibits ligand-independent and ligand-dependent 
actions in HSCs, warranting future studies of individual TGF ligands in liver fibrogenesis.  
 
Activin A and B additively and interdependently act on HSCs and macrophages 
Our study showed that the presence of both activin B and activin A is required to optimally 
promote liver injury progression. We showed that hepatic and systemic activin A was transiently 
increased at the acute phase of liver injury and was maintained at the pre-injury level during the 
long-lasting chronic phase. Although the neutralization of activin A alone produced beneficial 
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effects, they were weaker than those noted after the neutralization of activin B alone in both the 
prevention and reversal studies. Furthermore, we observed many additive or synergistic effects 
between activin B and A in vitro in macrophages and HSCs as well as in vivo in chronically injured 
livers, as described in the result section. For example, we showed a novel activin B and 
A/CXCL1/iNOS pathway that modulates macrophages. In response to immunological stimuli, 
iNOS is highly induced and generates a large amount of nitric oxide and hence promotes many 
pathological processes, including liver fibrosis of diverse etiology160-162. Identification of this 
pathway enabled us to gain important mechanistic insights into the actions of activin B and A. 
Another example is that the upregulation of CTGF and TGFβ1 gene expression requires the 
collaboration of activin B and A in chronically damaged livers. Most strikingly, inactivating both 
activin B and A yielded the most profound beneficial effects across our structural and functional 
assessments compared to those noted after inactivating activin B or A alone. These observations 
indicate that, as liver injury progresses, elevated activin B needs constitutive activin A for the 
activation of certain cellular programs that otherwise would not be initiated by a single ligand. 
Thus, unchanged activin A is not only an auxiliary factor, but also an essential collaborator, of 
increased activin B, on which individual cellular programs depend, in persistently injured livers. 
This represents a novel mode of action of TGFβ ligands in general and a new mechanism governing 
the actions of activins B and A in specific.  
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Neutralization of both activin A and B is highly efficient in preventing and regressing liver 
fibrosis 
 
Our pre-clinical studies showed that targeting activin B or ideally both activin B and A is a 
promising strategy to prevent and even reverse liver fibrosis. In addition to blocking activin A and 
B, neutralization of both activin A and B produced additive or synergistic effect that can be 
attributed to the blocking of activin AB; partial inactivation of activin AC, activin AE, activin BC, 
inhibin A, and inhibin B; and potential interactions between activin A/Smad2/3 signaling and 
activin B/Smad1/5/8 pathway. Anti-activin A antibody neutralizes activin A and any of the 
heterodimers having inhibin βA subunit, whereas anti-activin B antibody blocks activin B and 
partially blocks any of the heterodimers having inhibin βB subunit. This broad-spectrum 
neutralization of multiple activins and inhibins provides enhanced anti-fibrotic and anti-
inflammatory effects. Furthermore, the inhibition of both of Smad2/3 and Smad1/5/8 pathways 
supports the profound anti-fibrotic efficacy. Both pathways share Smad4, the common 
transcription factor, which might explain the additive or synergistic effects after combined 
activation or inhibition of activin A and B. Improved understanding of TGFβ signaling in 
homeostasis and pathophysiology has accelerated continuous preclinical and clinical efforts 
targeting its ligands, receptors, or Smads for therapeutic benefits, including reversing organ 
fibrosis. However, few studies have shown positive patient outcomes largely because of off-target 
complications3 64. Thus far, Pirfenidone is the only small-molecule TGFβ signaling inhibitor 
approved for the treatment of human idiopathic pulmonary fibrosis. It has significant adverse 
effects in the gastrointestinal tract and skin132. A soluble ActRIIB, ACE-031 has been tested in 
clinical trials in healthy volunteers and patients with Duchene Muscular Dystrophy163. Soluble 
ActRIIB binds to various TGFβ superfamily ligands, including GDF5, GDF8, GDF11, activin A, 
activin B, activin C, activin E, Nodal, BMP2, BMP4, BMP6/7, BMP9, and BMP10 and other 
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negative regulators of muscle mass. Clinically, ActRIIB showed pronounced effect on increasing 
skeletal muscle growth, but caused bleeding, which might be attributed to its non-specific binding 
to TGFβ superfamily ligands, limited its clinical application164. Although our study has some 
limitations in that the PK/PD of the antibodies was not determined and thus the dosing regimens 
used might not be optimal, once per week administration of activin B antibody alone or activin B 
and A dual antibodies showed high therapeutic efficacy. Our results might form a basis for further 
translational development of this strategy.  
 
Liver fibrosis is mediated by multiple cell populations 
The development of hepatic fibrogenesis is orchestrated by many cell populations in the liver, such 
as hepatocytes, HSCs, and macrophages. Other cell types also participate in liver fibrosis, 
including endothelial cells, progenitor cells, and natural killer cells. At present, therapeutic targets 
of liver fibrosis only focus on myofibroblast inactivation and apoptosis and/or macrophage 
phenotype switch. Other cell types might need to be considered in liver pathogenesis. Recently, 
accumulating evidence implies that epigenetic regulation might affect liver fibrosis development, 
which is represented by DNA methylation and histone modification165-167. The proteins and non-
coding regulatory RNA molecules involved in epigenetic mechanism might reveal new biomarkers 
and therapeutic targets for liver fibrosis. In the present study, we identified activin B as a novel 
biomarker and therapeutic target of liver fibrosis. Interestingly, serum activin B was also elevated 
in idiopathic pulmonary fibrosis, indicating that it might be involved in fibrogenesis in other 
organs168 169.  
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3.13 Conclusion 
In summary, we identified activin B as a potent driver, potential clinical biomarker, and a 
promising therapeutic target of liver fibrosis. Based on our findings, we propose the following 
theory (Figure 3.13). Irrespective of the etiology, chronically injured livers constantly produce 
increased activin B. Synergistically with constitutive activin A, it promotes hepatocyte injury and 
possibly trans-differentiation; modulates macrophages and other immune cells to secrete 
inflammatory cytokines through CXCL1/iNOS, TWEAK/Fn14, and other signaling pathways; and, 
most importantly, initiates and maintains the activation of HSCs by increasing the expression of 
pro-fibrotic genes, including CTGF and TGFβ1. Thus, activin B potently promotes liver 
fibrogenesis. This theory directs our future investigations to elucidate activin B- and A-triggered 
signaling pathways and their functions in each liver cell population during the progression of liver 
fibrosis. 
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Figure 3.11   Scheme of the proposed role of activin B and activin A in promoting hepatic 
fibrogenesis 
Hepatic fibrogenesis mediated by activin B and activin A is orchestrated by multiple cell types, 
including hepatocytes, HSCs, and KCs. (1) Liver injury (for example by CCl4 and alcohol) 
causes parenchymal cell (hepatocytes and cholangiocytes) necrosis and/or apoptosis. (2) The 
injured hepatocytes release various growth factors, including activin A and activin B, which in 
turn activate hepatic stellate cells, attract and activate Kupffer cells, and trans-differentiate 
hepatocytes to myofibroblasts as autocrine cytokines. (3) The sustained elevation of activin B 
and constitutive activin A, in particular, lead to the trans-differentiation of hepatic stellate cells 
and hepatocytes into myofibroblasts, which express profibrotic genes, including ACTA1, 
collagen I, CTGF, and TGFβ1. Activin A and activin B activate macrophages that highly express 
inflammatory genes such as TWEAK, Fn14, and CCL2. TWEAK/Fn14 and CXCL1/iNOS 
signaling promotes a hepatic inflammatory response. (4) Synergistic induction by activin A and 
activin B of CXCL1 and iNOS in macrophages and CTGF, GNDF, IL-6, IL-1β, caspase 3, and 
CXCL1 in HSCs promote hepatocytes apoptosis, hepatic inflammation, and liver fibrogenesis. 
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3.14 Future directions 
Our results reveal that activin B is a novel biomarker and mediator of liver fibrosis. Circulating 
activin B level is associated with fibrosis progression in preclinical liver fibrosis induced by 
hepatotoxins such as CCl4 or ethanol and cholestasis and in human NASH and alcoholic liver 
diseases. Further clinical evidence from liver and serum samples from patients with NASH and 
ALD as well as other chronic liver diseases, including chronic virus hepatitis or autoimmune 
hepatitis, is required. Neutralization of activin A or activin B alone prevents and even reverses 
hepatotoxin-induced liver fibrosis, whereas neutralization of both enhances the anti-fibrotic effect 
and optimally improves liver function. Antagonizing both activin A and activin B signaling seems 
to be a promising target for preventing and reversing liver fibrosis. Thus, a conjugate antibody 
needs to be developed to block both activin A and B. Dual antibody generation and its PK/PD 
results might allow its evaluation in preclinical animal models and even in clinical trials of liver 
fibrosis or NASH.   
 
In the microarray study, we found a novel transcription factor, the SRY-related High Mobility 
Group box transcription factor 4 (SOX4), which was upregulated with activin A, activin B, and 
TGFβ1 in HSCs. In developmental biology, gene knockout studies revealed that SOX4 
cooperatively with SOX9 acts as a pivotal transcription factor and regulator of biliary 
development170. The role of SOX4 in hepatic fibrogenesis has not yet been determined. The 
mechanism of SOX4 in hepatic fibrogenesis, especially in HSC activation and differentiation, 
needs to be further investigated. Liver-specific or stellate cell-specific SOX4 knockout or 
overexpression studies might enable the elucidation of target genes and their effects on septa 
structure formation in liver fibrosis development. Further studies are required to investigate 
whether activin A and B mediate hepatic fibrogenesis through SOX4 in HSCs.   
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In conclusion, future translational studies are required to develop activin B as a potential biomarker, 
generate dual antibodies, and conduct evaluations in rodent models and clinical patients, as well 
as to determine the mechanism of SOX4 in activin-mediated liver fibrosis.  
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